WO2016046817A1 - Compositions and methods for selective gi tract delivery - Google Patents
Compositions and methods for selective gi tract delivery Download PDFInfo
- Publication number
- WO2016046817A1 WO2016046817A1 PCT/IL2015/050951 IL2015050951W WO2016046817A1 WO 2016046817 A1 WO2016046817 A1 WO 2016046817A1 IL 2015050951 W IL2015050951 W IL 2015050951W WO 2016046817 A1 WO2016046817 A1 WO 2016046817A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- matter
- vitamin
- alcohol
- group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract description 66
- 238000000034 method Methods 0.000 title description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 113
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 84
- 230000015556 catabolic process Effects 0.000 claims abstract description 26
- 230000003474 anti-emetic effect Effects 0.000 claims abstract description 14
- 239000002111 antiemetic agent Substances 0.000 claims abstract description 13
- 230000001965 increasing effect Effects 0.000 claims abstract description 11
- 206010021518 Impaired gastric emptying Diseases 0.000 claims abstract description 10
- 208000001288 gastroparesis Diseases 0.000 claims abstract description 10
- 230000000202 analgesic effect Effects 0.000 claims abstract description 9
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 9
- 239000011859 microparticle Substances 0.000 claims description 68
- 239000011247 coating layer Substances 0.000 claims description 58
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 50
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 claims description 48
- 239000004480 active ingredient Substances 0.000 claims description 43
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 claims description 41
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 40
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 40
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 38
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 claims description 36
- 238000000576 coating method Methods 0.000 claims description 33
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 27
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims description 27
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims description 27
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 25
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 25
- 235000005875 quercetin Nutrition 0.000 claims description 25
- 229960001285 quercetin Drugs 0.000 claims description 25
- 239000007788 liquid Substances 0.000 claims description 24
- 235000013361 beverage Nutrition 0.000 claims description 23
- 235000002780 gingerol Nutrition 0.000 claims description 23
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 22
- 239000000499 gel Substances 0.000 claims description 21
- 229960005559 sulforaphane Drugs 0.000 claims description 21
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 claims description 20
- 235000012754 curcumin Nutrition 0.000 claims description 20
- 229940109262 curcumin Drugs 0.000 claims description 20
- 239000004148 curcumin Substances 0.000 claims description 20
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 20
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 20
- 229940087305 limonene Drugs 0.000 claims description 20
- 235000001510 limonene Nutrition 0.000 claims description 20
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 20
- 235000015487 sulforaphane Nutrition 0.000 claims description 20
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 19
- 229960003237 betaine Drugs 0.000 claims description 19
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 19
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 claims description 18
- 229940043357 mangiferin Drugs 0.000 claims description 18
- 150000004175 parthenolide derivatives Chemical class 0.000 claims description 18
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 17
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 17
- 235000021283 resveratrol Nutrition 0.000 claims description 17
- 229940016667 resveratrol Drugs 0.000 claims description 17
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 claims description 16
- HITDPRAEYNISJU-UHFFFAOYSA-N amenthoflavone Natural products Oc1ccc(cc1)C2=COc3c(C2=O)c(O)cc(O)c3c4cc(ccc4O)C5=COc6cc(O)cc(O)c6C5=O HITDPRAEYNISJU-UHFFFAOYSA-N 0.000 claims description 16
- YUSWMAULDXZHPY-UHFFFAOYSA-N amentoflavone Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 YUSWMAULDXZHPY-UHFFFAOYSA-N 0.000 claims description 16
- HVSKSWBOHPRSBD-UHFFFAOYSA-N amentoflavone Natural products Oc1ccc(cc1)C2=CC(=O)c3c(O)cc(O)c(c3O2)c4cc(ccc4O)C5=COc6cc(O)cc(O)c6C5=O HVSKSWBOHPRSBD-UHFFFAOYSA-N 0.000 claims description 16
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 16
- NQJGJBLOXXIGHL-UHFFFAOYSA-N podocarpusflavone A Natural products COc1ccc(cc1)C2=CC(=O)c3c(O)cc(O)c(c3O2)c4cc(ccc4O)C5=COc6cc(O)cc(O)c6C5=O NQJGJBLOXXIGHL-UHFFFAOYSA-N 0.000 claims description 16
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 16
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 claims description 15
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 claims description 15
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 claims description 15
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 claims description 15
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 claims description 15
- 229940120668 salicin Drugs 0.000 claims description 15
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 14
- 229920001800 Shellac Polymers 0.000 claims description 14
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 14
- 229960004308 acetylcysteine Drugs 0.000 claims description 14
- 229930182494 ginsenoside Natural products 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 14
- 235000013874 shellac Nutrition 0.000 claims description 14
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 claims description 12
- 229930003427 Vitamin E Natural products 0.000 claims description 11
- 229920002494 Zein Polymers 0.000 claims description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 11
- 235000019165 vitamin E Nutrition 0.000 claims description 11
- 229940046009 vitamin E Drugs 0.000 claims description 11
- 239000011709 vitamin E Substances 0.000 claims description 11
- 239000005019 zein Substances 0.000 claims description 11
- 229940093612 zein Drugs 0.000 claims description 11
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 10
- 229920002770 condensed tannin Polymers 0.000 claims description 10
- 239000003925 fat Substances 0.000 claims description 10
- 235000019197 fats Nutrition 0.000 claims description 10
- 229930184727 ginkgolide Natural products 0.000 claims description 10
- 235000019136 lipoic acid Nutrition 0.000 claims description 10
- 229960002663 thioctic acid Drugs 0.000 claims description 10
- 239000011701 zinc Substances 0.000 claims description 10
- 229910052725 zinc Inorganic materials 0.000 claims description 10
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 claims description 9
- 229930003316 Vitamin D Natural products 0.000 claims description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 9
- 230000003931 cognitive performance Effects 0.000 claims description 9
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 claims description 9
- 235000011797 eriodictyol Nutrition 0.000 claims description 9
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 claims description 9
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 claims description 9
- 235000019152 folic acid Nutrition 0.000 claims description 9
- 239000011724 folic acid Substances 0.000 claims description 9
- 235000019166 vitamin D Nutrition 0.000 claims description 9
- 239000011710 vitamin D Substances 0.000 claims description 9
- 229940046008 vitamin d Drugs 0.000 claims description 9
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- -1 SAMe Chemical compound 0.000 claims description 8
- 229960001948 caffeine Drugs 0.000 claims description 8
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 8
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- 229960000278 theophylline Drugs 0.000 claims description 8
- 229930091371 Fructose Natural products 0.000 claims description 7
- 239000005715 Fructose Substances 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 7
- 235000010443 alginic acid Nutrition 0.000 claims description 7
- 229920000615 alginic acid Polymers 0.000 claims description 7
- 241000736299 Adiantum Species 0.000 claims description 6
- 241000219318 Amaranthus Species 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 240000000691 Houttuynia cordata Species 0.000 claims description 6
- 235000013719 Houttuynia cordata Nutrition 0.000 claims description 6
- 235000012191 Minthostachys mollis Nutrition 0.000 claims description 6
- 241000034013 Minthostachys mollis Species 0.000 claims description 6
- 241000264279 Sargassum fusiforme Species 0.000 claims description 6
- 241000158087 Usnea florida Species 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 239000001814 pectin Substances 0.000 claims description 6
- 229920001277 pectin Polymers 0.000 claims description 6
- 235000010987 pectin Nutrition 0.000 claims description 6
- 150000003751 zinc Chemical class 0.000 claims description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 5
- 239000004381 Choline salt Substances 0.000 claims description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
- 229920002907 Guar gum Polymers 0.000 claims description 5
- 241000899950 Salix glauca Species 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000013522 chelant Substances 0.000 claims description 5
- 235000019417 choline salt Nutrition 0.000 claims description 5
- VVYPIVJZLVJPGU-UHFFFAOYSA-L copper;2-aminoacetate Chemical compound [Cu+2].NCC([O-])=O.NCC([O-])=O VVYPIVJZLVJPGU-UHFFFAOYSA-L 0.000 claims description 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 5
- 229920001249 ethyl cellulose Polymers 0.000 claims description 5
- 229940014144 folate Drugs 0.000 claims description 5
- 239000000665 guar gum Substances 0.000 claims description 5
- 235000010417 guar gum Nutrition 0.000 claims description 5
- 229960002154 guar gum Drugs 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229940041616 menthol Drugs 0.000 claims description 5
- 150000003248 quinolines Chemical class 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 235000019156 vitamin B Nutrition 0.000 claims description 5
- 239000011720 vitamin B Substances 0.000 claims description 5
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 4
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims description 4
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 4
- 235000019482 Palm oil Nutrition 0.000 claims description 4
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims description 4
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 235000021307 Triticum Nutrition 0.000 claims description 4
- 244000098338 Triticum aestivum Species 0.000 claims description 4
- 239000005862 Whey Substances 0.000 claims description 4
- 102000007544 Whey Proteins Human genes 0.000 claims description 4
- 108010046377 Whey Proteins Proteins 0.000 claims description 4
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003240 coconut oil Substances 0.000 claims description 4
- 235000019864 coconut oil Nutrition 0.000 claims description 4
- 235000008384 feverfew Nutrition 0.000 claims description 4
- 229960000304 folic acid Drugs 0.000 claims description 4
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 claims description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims description 4
- 159000000003 magnesium salts Chemical class 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000002540 palm oil Substances 0.000 claims description 4
- 235000008975 pantethine Nutrition 0.000 claims description 4
- 239000011581 pantethine Substances 0.000 claims description 4
- 229960000903 pantethine Drugs 0.000 claims description 4
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims description 4
- 108060006613 prolamin Proteins 0.000 claims description 4
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 229940096998 ursolic acid Drugs 0.000 claims description 4
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 4
- 244000215068 Acacia senegal Species 0.000 claims description 3
- 229920000856 Amylose Polymers 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 3
- 102000006395 Globulins Human genes 0.000 claims description 3
- 108010044091 Globulins Proteins 0.000 claims description 3
- 229920000084 Gum arabic Polymers 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 claims description 3
- 229930195714 L-glutamate Natural products 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 108010084695 Pea Proteins Proteins 0.000 claims description 3
- 108010073771 Soybean Proteins Proteins 0.000 claims description 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000000205 acacia gum Substances 0.000 claims description 3
- 229960002433 cysteine Drugs 0.000 claims description 3
- 108010016616 cysteinylglycine Proteins 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 229940091250 magnesium supplement Drugs 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 235000019702 pea protein Nutrition 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920000193 polymethacrylate Polymers 0.000 claims description 3
- 150000004728 pyruvic acid derivatives Chemical class 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 229940001941 soy protein Drugs 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 2
- 235000013073 Acorus gramineus Nutrition 0.000 claims description 2
- 244000001632 Acorus gramineus Species 0.000 claims description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 2
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 claims description 2
- MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 claims description 2
- 239000005973 Carvone Substances 0.000 claims description 2
- 241000723346 Cinnamomum camphora Species 0.000 claims description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 2
- 235000017048 Garcinia mangostana Nutrition 0.000 claims description 2
- 240000006053 Garcinia mangostana Species 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
- 240000003296 Petasites japonicus Species 0.000 claims description 2
- 235000003823 Petasites japonicus Nutrition 0.000 claims description 2
- 241000208966 Polygala Species 0.000 claims description 2
- 244000197580 Poria cocos Species 0.000 claims description 2
- 235000008599 Poria cocos Nutrition 0.000 claims description 2
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229960003767 alanine Drugs 0.000 claims description 2
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 2
- 229940093265 berberine Drugs 0.000 claims description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 2
- 235000001436 butterbur Nutrition 0.000 claims description 2
- 229960000846 camphor Drugs 0.000 claims description 2
- 229930008380 camphor Natural products 0.000 claims description 2
- 235000004654 carnosol Nutrition 0.000 claims description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 229940025878 hesperidin Drugs 0.000 claims description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 2
- 235000008777 kaempferol Nutrition 0.000 claims description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims description 2
- 239000008164 mustard oil Substances 0.000 claims description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000018192 pine bark supplement Nutrition 0.000 claims description 2
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 2
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 2
- 235000015398 thunder god vine Nutrition 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims 2
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims 2
- 229920002125 Sokalan® Polymers 0.000 claims 2
- 229940053326 magnesium salt Drugs 0.000 claims 2
- 244000192528 Chrysanthemum parthenium Species 0.000 claims 1
- 239000004201 L-cysteine Substances 0.000 claims 1
- 235000013878 L-cysteine Nutrition 0.000 claims 1
- 229920001991 Proanthocyanidin Polymers 0.000 claims 1
- 235000019486 Sunflower oil Nutrition 0.000 claims 1
- 239000004203 carnauba wax Substances 0.000 claims 1
- 235000013869 carnauba wax Nutrition 0.000 claims 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 claims 1
- 239000001761 ethyl methyl cellulose Substances 0.000 claims 1
- 229940087603 grape seed extract Drugs 0.000 claims 1
- 235000002532 grape seed extract Nutrition 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 239000002600 sunflower oil Substances 0.000 claims 1
- 239000001717 vitis vinifera seed extract Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 45
- 239000000047 product Substances 0.000 abstract description 36
- 230000019771 cognition Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 239000000284 extract Substances 0.000 description 65
- 239000002245 particle Substances 0.000 description 58
- 230000002255 enzymatic effect Effects 0.000 description 41
- 230000002378 acidificating effect Effects 0.000 description 32
- 210000002784 stomach Anatomy 0.000 description 31
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 24
- 239000008103 glucose Substances 0.000 description 23
- 239000004615 ingredient Substances 0.000 description 23
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 230000003042 antagnostic effect Effects 0.000 description 19
- 229940002508 ginger extract Drugs 0.000 description 19
- 235000020708 ginger extract Nutrition 0.000 description 19
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 16
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 16
- 229930003471 Vitamin B2 Natural products 0.000 description 16
- 238000005538 encapsulation Methods 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 16
- 238000011084 recovery Methods 0.000 description 16
- 229960002477 riboflavin Drugs 0.000 description 16
- 235000019164 vitamin B2 Nutrition 0.000 description 16
- 239000011716 vitamin B2 Substances 0.000 description 16
- 230000035807 sensation Effects 0.000 description 15
- 235000019615 sensations Nutrition 0.000 description 15
- 210000000813 small intestine Anatomy 0.000 description 15
- 230000001270 agonistic effect Effects 0.000 description 14
- 229940068196 placebo Drugs 0.000 description 14
- 239000000902 placebo Substances 0.000 description 14
- 230000008901 benefit Effects 0.000 description 13
- 230000001149 cognitive effect Effects 0.000 description 13
- 239000004208 shellac Substances 0.000 description 13
- 229940113147 shellac Drugs 0.000 description 13
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 13
- 244000194101 Ginkgo biloba Species 0.000 description 12
- 235000008100 Ginkgo biloba Nutrition 0.000 description 12
- 244000273928 Zingiber officinale Species 0.000 description 12
- 235000006886 Zingiber officinale Nutrition 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 235000008397 ginger Nutrition 0.000 description 12
- 244000046146 Pueraria lobata Species 0.000 description 11
- 235000010575 Pueraria lobata Nutrition 0.000 description 11
- 108010055615 Zein Proteins 0.000 description 11
- 229960003638 dopamine Drugs 0.000 description 11
- 230000004060 metabolic process Effects 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 10
- 229960001231 choline Drugs 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 235000019640 taste Nutrition 0.000 description 10
- 235000005979 Citrus limon Nutrition 0.000 description 9
- 244000131522 Citrus pyriformis Species 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 229960004203 carnitine Drugs 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 8
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 8
- 230000005032 impulse control Effects 0.000 description 8
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 235000019158 vitamin B6 Nutrition 0.000 description 8
- 239000011726 vitamin B6 Substances 0.000 description 8
- 229940011671 vitamin b6 Drugs 0.000 description 8
- 235000004936 Bromus mango Nutrition 0.000 description 7
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 7
- 240000007228 Mangifera indica Species 0.000 description 7
- 235000014826 Mangifera indica Nutrition 0.000 description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 7
- 235000009184 Spondias indica Nutrition 0.000 description 7
- 229930003537 Vitamin B3 Natural products 0.000 description 7
- 229930003571 Vitamin B5 Natural products 0.000 description 7
- 229930003761 Vitamin B9 Natural products 0.000 description 7
- 206010047700 Vomiting Diseases 0.000 description 7
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 7
- 229960002079 calcium pantothenate Drugs 0.000 description 7
- 230000003920 cognitive function Effects 0.000 description 7
- 230000030135 gastric motility Effects 0.000 description 7
- 229940087559 grape seed Drugs 0.000 description 7
- 230000010365 information processing Effects 0.000 description 7
- 230000031891 intestinal absorption Effects 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 7
- 230000015654 memory Effects 0.000 description 7
- 230000007659 motor function Effects 0.000 description 7
- 229960003512 nicotinic acid Drugs 0.000 description 7
- 238000001694 spray drying Methods 0.000 description 7
- 235000019160 vitamin B3 Nutrition 0.000 description 7
- 239000011708 vitamin B3 Substances 0.000 description 7
- 235000009492 vitamin B5 Nutrition 0.000 description 7
- 239000011675 vitamin B5 Substances 0.000 description 7
- 235000019159 vitamin B9 Nutrition 0.000 description 7
- 239000011727 vitamin B9 Substances 0.000 description 7
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 6
- 235000011201 Ginkgo Nutrition 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 6
- 229930003779 Vitamin B12 Natural products 0.000 description 6
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 6
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 6
- 239000005516 coenzyme A Substances 0.000 description 6
- 229940093530 coenzyme a Drugs 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 6
- 230000001771 impaired effect Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 235000019645 odor Nutrition 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 6
- 235000019163 vitamin B12 Nutrition 0.000 description 6
- 239000011715 vitamin B12 Substances 0.000 description 6
- 102100038074 5'-AMP-activated protein kinase subunit beta-1 Human genes 0.000 description 5
- 244000035851 Chrysanthemum leucanthemum Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 5
- 208000019695 Migraine disease Diseases 0.000 description 5
- 206010028813 Nausea Diseases 0.000 description 5
- 102000003566 TRPV1 Human genes 0.000 description 5
- 101150016206 Trpv1 gene Proteins 0.000 description 5
- 230000003935 attention Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 210000001198 duodenum Anatomy 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 206010027599 migraine Diseases 0.000 description 5
- 230000008693 nausea Effects 0.000 description 5
- 238000005192 partition Methods 0.000 description 5
- 102100040385 5-hydroxytryptamine receptor 4 Human genes 0.000 description 4
- 101710150225 5-hydroxytryptamine receptor 4 Proteins 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- 206010019133 Hangover Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241001504070 Huperzia Species 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- 102000011990 Sirtuin Human genes 0.000 description 4
- 108050002485 Sirtuin Proteins 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 229940072056 alginate Drugs 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229960003624 creatine Drugs 0.000 description 4
- 239000006046 creatine Substances 0.000 description 4
- 235000007336 cyanidin Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 229960004667 ethyl cellulose Drugs 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000001630 jejunum Anatomy 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 235000010919 Copernicia prunifera Nutrition 0.000 description 3
- 244000180278 Copernicia prunifera Species 0.000 description 3
- 235000003222 Helianthus annuus Nutrition 0.000 description 3
- 244000020551 Helianthus annuus Species 0.000 description 3
- 235000008584 Hovenia dulcis Nutrition 0.000 description 3
- 244000010000 Hovenia dulcis Species 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 239000008393 encapsulating agent Substances 0.000 description 3
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229960002737 fructose Drugs 0.000 description 3
- SQOJOAFXDQDRGF-WJHVHIKBSA-N ginkgolide B Natural products O=C1[C@@H](C)[C@@]2(O)[C@@H]([C@H](O)[C@]34[C@@H]5OC(=O)[C@]23O[C@H]2OC(=O)[C@H](O)[C@@]42[C@H](C(C)(C)C)C5)O1 SQOJOAFXDQDRGF-WJHVHIKBSA-N 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 229960002900 methylcellulose Drugs 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- HCXVJBMSMIARIN-ZETWWWAOSA-N 24alpha-Ethyl-koprostanol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-ZETWWWAOSA-N 0.000 description 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 2
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 2
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010001605 Alcohol poisoning Diseases 0.000 description 2
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 2
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 2
- 235000013793 astaxanthin Nutrition 0.000 description 2
- 239000001168 astaxanthin Substances 0.000 description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 2
- 229940022405 astaxanthin Drugs 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- SQOJOAFXDQDRGF-MMQTXUMRSA-N ginkgolide-b Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13[C@@H](O)[C@@H]1OC(=O)[C@@H](C)[C@]21O SQOJOAFXDQDRGF-MMQTXUMRSA-N 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940084038 salix alba bark extract Drugs 0.000 description 2
- 230000010332 selective attention Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940045999 vitamin b 12 Drugs 0.000 description 2
- UGJAEDFOKNAMQD-DVQDXYAYSA-N (-)-Falcarinol Natural products CCCCCCC\C=C\CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-DVQDXYAYSA-N 0.000 description 1
- XXAUOPDVAKGRPR-WYCDGMCDSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-azaniumylpropanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoate Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O XXAUOPDVAKGRPR-WYCDGMCDSA-N 0.000 description 1
- UGJAEDFOKNAMQD-MQNTZWLQSA-N (3S,9Z)-1,9-Heptadecadiene-4,6-diyn-3-ol Chemical compound CCCCCCC\C=C/CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-MQNTZWLQSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- 108091005482 5-HT4 receptors Proteins 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000298715 Actinidia chinensis Species 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 244000308180 Brassica oleracea var. italica Species 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 1
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 241000207934 Eriodictyon Species 0.000 description 1
- 235000002683 Eriodictyon californicum Nutrition 0.000 description 1
- UGJAEDFOKNAMQD-UHFFFAOYSA-N Falcarinol Natural products CCCCCCCC=CCC#CC#CC(O)C=C UGJAEDFOKNAMQD-UHFFFAOYSA-N 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- AMOGMTLMADGEOQ-FNZROXQESA-N Ginkgolide C Chemical compound O([C@H]1O2)C(=O)[C@H](O)C31[C@]14[C@@H](O)[C@@H]5OC(=O)[C@@H](C)[C@]5(O)[C@@]12C(=O)O[C@@H]4[C@@H](O)[C@H]3C(C)(C)C AMOGMTLMADGEOQ-FNZROXQESA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 108010009513 Mitochondrial Aldehyde Dehydrogenase Proteins 0.000 description 1
- 102000009645 Mitochondrial Aldehyde Dehydrogenase Human genes 0.000 description 1
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 229940123223 TRPA1 agonist Drugs 0.000 description 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 235000019888 Vivapur Nutrition 0.000 description 1
- AYFQFFKARHROLX-UHFFFAOYSA-N [Mg].[Mg].[Mg].[Mg].[Mg].[Mg] Chemical compound [Mg].[Mg].[Mg].[Mg].[Mg].[Mg] AYFQFFKARHROLX-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical group [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940018333 calcium pyruvate Drugs 0.000 description 1
- UZWMCCLZMHPPKW-UHFFFAOYSA-L calcium;2-oxopropanoate Chemical compound [Ca+2].CC(=O)C([O-])=O.CC(=O)C([O-])=O UZWMCCLZMHPPKW-UHFFFAOYSA-L 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- 229950011318 cannabidiol Drugs 0.000 description 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
- 229940043234 carbomer-940 Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- JRLHSTVTOOELAF-KRWDZBQOSA-N dehydrofalcarinol Natural products O[C@@H](C=C)C#CC#CCC=CCCCCCC=C JRLHSTVTOOELAF-KRWDZBQOSA-N 0.000 description 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000016253 exhaustion Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940001448 feverfew extract Drugs 0.000 description 1
- 235000020702 feverfew extract Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- FPUXKXIZEIDQKW-MFJLLLFKSA-N ginkgolide A Natural products O=C1[C@H](C)[C@@]2(O)[C@@H](O1)C[C@]13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)[C@]31[C@@H](C(C)(C)C)C4 FPUXKXIZEIDQKW-MFJLLLFKSA-N 0.000 description 1
- AMOGMTLMADGEOQ-DPFZUGDXSA-N ginkgolide C Natural products O=C1[C@@H](C)[C@]2(O)[C@H]([C@H](O)[C@@]34[C@H]5[C@H](O)[C@@H](C(C)(C)C)[C@]63[C@H](O)C(=O)O[C@H]6O[C@@]24C(=O)O5)O1 AMOGMTLMADGEOQ-DPFZUGDXSA-N 0.000 description 1
- FPUXKXIZEIDQKW-VKMVSBOZSA-N ginkgolide-a Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13C[C@@H]1OC(=O)[C@@H](C)[C@]21O FPUXKXIZEIDQKW-VKMVSBOZSA-N 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 231100000568 intoxicate Toxicity 0.000 description 1
- 230000002673 intoxicating effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229940115160 morning after Drugs 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000020733 paullinia cupana extract Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000003748 selenium group Chemical class *[Se]* 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- BUDVAFFSFQXKRC-UHFFFAOYSA-N zinc Chemical compound [Zn].[Zn].[Zn].[Zn].[Zn].[Zn] BUDVAFFSFQXKRC-UHFFFAOYSA-N 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to compositions and methods of using same for selective delivery of active ingredients in the GI tract.
- Embodiments of the present invention relate to a liquid (aqueous) preparation incorporating soluble and/or suspended bioactive ingredients for remedying the effects of excessive alcohol consumption.
- Alcohol is the most popular legal intoxicant around the globe.
- the current global market for alcoholic beverages is in excess of $900B a year.
- the average daily consumption of alcohol per person is in excess of 40 grams of pure alcohol. This average daily alcohol consumption quantity is comparable to the consumption of 3 beers.
- Alcohol consumption intoxicates the human body and results in a wide variety of short term and not infrequently long term negative side effects and outcomes.
- the first metabolic intermediate generated through alcohol metabolism in the human body is acetaldehyde, a toxic compound even at very low concentrations. Therefore, in order to avoid irreversible short term health damages and optionally death, the rate of alcohol metabolism by the human body is limited by its ability to metabolize and remove blood and/or cell-attached and/or tissue-attached acetaldehyde. As a result, the rate of blood alcohol metabolism is quite slow, typically ranging between 0.03 - 0.15 gram percent per hour by occasional alcohol consumers, and up to 0.15 - 0.25 gram percent per hour by binge and alcoholic drinkers.
- the most critical activity impaired by blood alcohol and blood acetaldehyde is driving, which is materially negatively affected by the effect of alcohol and acetaldehyde on the brain, resulting in reduced cognitive and motor performance, and further accompanied by the impairment of judgment and sliding into reckless behavior and undesired risk taking.
- BAC level is on the decreasing slope
- SobrietolTM takes a different approach, by incorporating alcohol metabolizing enzymes, which target the decomposition of the consumed alcohol in the stomach and intestines, and thus reduce the absorption of alcohol into systemic circulation.
- alcohol metabolizing enzymes which target the decomposition of the consumed alcohol in the stomach and intestines, and thus reduce the absorption of alcohol into systemic circulation.
- Party SmartTM A third approach is taken by Party SmartTM. This product incorporates a number of plant extracts, which claim targeting the protection of liver damage through anti-oxidant activities and through affecting increased alcohol metabolizing enzymes' activity. Similar to the other above-mentioned products, Party SmartTM needs to be consumed prior to alcohol consumption. Human data demonstrating the impact of these products on hangover and blood alcohol is very limited, or demonstrate very limited efficacy.
- composition-of-matter comprising at least two types of microparticles each formed from an active ingredient core encapsulated by at least one coating material, the at least two types of said microparticles being differentiated by the active ingredient or the at least one coating material.
- each of the at least two types of said microparticles is capable of releasing the active ingredient at a different region of a GI tract.
- the microparticles have a diameter of 25-100 microns.
- the active ingredient core of the composition-of-matter comprises at least one of: (a) dietary supplements having cognitive and motor function; (b) dietary supplements having anti-gastroparesis, antiemetic, analgesic and anti-inflammatory activities; and/or (c) dietary supplements being capable of increasing alcohol catabolism.
- composition-of-matter comprises (a) and (b), (b) and (c) or (a) and (c).
- At least some of the dietary supplements of (a)-(c) are encapsulated within microparticles.
- composition-of-matter is formulated as a beverage.
- composition-of-matter is formulated as a gel.
- a pH of the beverage or the gel is 2.4-3.5.
- the beverage or gel do not contain enzymes.
- the dietary supplements having cognitive and motor function are selected from the group having antagonistic activity against GABA, Adenosine Al, AchE, Dopamine Dl, Dopamine D2, Dopamine D3, 5-HT1A, 5-HT2 and 5HT3; and; agonistic activity against Glutamate, Adenosine A2A, 5-HT1B and 5-HT4
- the dietary supplement having antagonistic activity against GABA is selected from the group consisting of Bilobalide, Ginkgolides (A, B & C), Puerarin, Resveratrol, Quercetin, Curcumin, Caffeine, Theophylline, Amentoflavone, Dihydromyricetin and Copper Glycinate Chelate.
- the dietary supplement having antagonistic activity against Adenosine Al is selected from the group consisting of Caffeine and Theophylline.
- the dietary supplement having antagonistic activity against AchE is selected from the group consisting of Huperzine A and Rosmarinic acid.
- the dietary supplement having antagonistic activity against Dopamine Dl is selected from the group consisting of Ginkgolide A, Parthenolides, Salicin, Eriodictyol, N-Acetyl- Cysteine, Magnesium, Zinc, Amentoflavone, Adiantum venestum, Amaranthus virdis, Houttuynia cordata, Minthostachys mollis, Sargassum fusiforme and Usnea florida.
- the dietary supplement having antagonistic activity against Dopamine D2 is selected from the group consisting of Limonene, Parthenolides, Eriodictyol, N-Acetyl-Cysteine, Alpha Lipoic Acid, Magnesium, Zinc, Amentoflavone, Adiantum venestum, Amaranthus virdis, Houttuynia cordata, Minthostachys mollis, Sargassum fusiforme and Usnea florida
- the dietary supplement having antagonistic activity against Dopamine D3 is selected from the group consisting of Ginkgolide C, Parthenolides, Eriodictyol, N-Acetyl-Cysteine, Magnesium, Zinc, Amentoflavone, Adiantum venestum, Amaranthus virdis, Houttuynia cordata, Minthostachys mollis, Sargassum fusiforme and Usnea florida.
- the dietary supplement having antagonistic activity against 5-HT1A is selected from the group consisting of Limonene, Proanthocyanidins and Zinc.
- the dietary supplement having antagonistic activity against 5-HT2 is selected from the group consisting of Puerarin, Limonene, Quercetin, Parthenolides, Salicin, Sulforaphane, Proanthocyanidins and Menthol.
- the dietary supplement having antagonistic activity against 5-HT3 is selected from the group consisting of Bilobalide, Ginkgolide B, Quercetin, Gingerols, Shogaols, Parthenolides, Proanthocyanidins and Menthol.
- the dietary supplement having agonistic activity against Glutamate is selected from the group consisting of Bilobalide, Huperzine A, N-Acetyl-Cysteine, Acetyl-L-Carnitine, Glutamic acid, Glycine, L-Glutamate, L-aspartate, L- Alanine, Magnesium and Zinc.
- the dietary supplement having agonistic activity against Adenosine A2A is selected from the group consisting of Polygala Limonene, Tenuifolia, Acorus gramineus, and Poria cocos.
- the dietary supplement having agonistic activity against 5-HT1B is selected from the group consisting of Limonene, Gingerols, Shogaols, Sulforaphane, Betaine and N- Acetyl-Cysteine.
- the dietary supplement having agonistic activity against 5-HT4 is selected from the group consisting of Mangiferin.
- the dietary supplements having anti-gastroparesis, antiemetic, analgesic and anti-inflammatory activities are selected from the group having antagonistic activity against Dopamine Dl, Dopamine D2, Dopamine D3, 5-HT3; and; agonistic activity against CB 1, CB2, TRPA1, TRPV1, 5-HT4, and; further activity providing COX inhibition / suppression, Prostaglandin synthesis suppression, Histamine inhibition, AMPK upregulation and vascular spasm reduction.
- the dietary supplement having agonistic activity against CB 1 and/or CB2 is selected from the group consisting of Cannabidiol and Falcarinol
- the dietary supplement having agonistic activity against TRPA1 is selected from the group consisting of Shogaols, Zinc, Mustard oil and Carnosol.
- the dietary supplement having agonistic activity against TRPV1 is selected from the group consisting of Shogaols, Piperin, Magnesium, Omega-3, Achinacea, Carvone and Camphor.
- the dietary supplement having Cox inhibitor activity is selected from the group consisting of Curcumin, Thunder God Vine, Resveratrol, Quercetin, Kaempferol, Pycogenol, Parthenolides, EGCG, Ursolic acid, Berberine and Ginsenosides.
- the dietary supplement having Prostaglandin inhibitor activity is selected from the group consisting of Gingerols, Shogaols, Salicin and Hesperidin.
- the dietary supplement having Histamine inhibitor activity is selected from the group consisting of Quercetin, Vitamin C, Mangosteen, and Butterbur.
- the dietary supplements capable of increasing alcohol catabolism are selected from the group consisting of alcohol and acetaldehyde catabolism co-factors, acetate catabolism co- factors, an upregulator of ADH activity, an upregulator of ALDH activity, an upregulator of Cyp2El activity, an upregulator of NAD+ activity, an acetaldehyde binding agent, an upregulator or activator of AMPK and/or SIRT; and a down- regulator of CD38, CD157 and/or PARP.
- the dietary supplement is an Alcohol and/or Acetaldehyde catabolism co-factor selected from the group consisting of B Vitamins: 1,2,3,5,6,9 and 12, Pantethine, Vitamin E, TMG (Betaine), Choline salt, Zinc salt, SAMe, Nicotinamide, Folate / Folic acid and Alpha Lipoic Acid.
- the dietary supplement is an Acetate catabolism co-factor such as Co-enzyme A.
- the dietary supplement is an Acetaldehyde binding agent selected from the group consisting of Proanthocyanidins and Cysteinylglycine.
- the dietary supplement is an upregulator of ADH activity selected from the group consisting of Magnesium and Zinc.
- the dietary supplement is an upregulator of ALDH activity selected from the group consisting of Sulforaphane, N-Acetyl-Cysteine and Alpha Lipoic Acid.
- the dietary supplement is an upregulator of NAD+ activity selected from the group consisting of Resveratrol, Quercetin, Caffeine, Theophylline, Betaine / TMG, Choline, N-Acetyl-Cysteine, Alpha Lipoic Acid, Acetyl-L-Carnitine, Pyruvate, Co-Enzyme A and Fructose.
- an upregulator of NAD+ activity selected from the group consisting of Resveratrol, Quercetin, Caffeine, Theophylline, Betaine / TMG, Choline, N-Acetyl-Cysteine, Alpha Lipoic Acid, Acetyl-L-Carnitine, Pyruvate, Co-Enzyme A and Fructose.
- the dietary supplement is an upregulator of AMPK activity selected from the group consisting of Bilobalide, Puerarin, Resveratrol, Quercetin, Shogaols, Salicin, Sulforaphane, Menthol, Betaine / TMG, Choline, Alpha Lipoic Acid and Acetyl-L- Carnitine.
- an upregulator of AMPK activity selected from the group consisting of Bilobalide, Puerarin, Resveratrol, Quercetin, Shogaols, Salicin, Sulforaphane, Menthol, Betaine / TMG, Choline, Alpha Lipoic Acid and Acetyl-L- Carnitine.
- the dietary supplement is an upregulator of SIRT activity selected from the group consisting of Resveratrol, Quercetin, Curcumin, Sulforaphane, N-Acetyl-Cysteine and Fructose.
- the dietary supplement is a down-regulator of CD38 and/or CD 157 activity selected from the group consisting of Quercetin.
- the dietary supplement is a down-regulator of PARP activity selected from the group consisting of Quercetin, Caffeine, Theophylline, Curcumin, Sulforaphane, Eriodictyol, Betaine / TMG, N- Acetyl-Cysteine and Pyruvate.
- an article of manufacturing comprising a container having two environmentally isolated compartments, a first compartment including the composition-of-matter of claim 1 and, a second compartment including a liquid, wherein at least a portion of the dietary supplements of (a), (b) and/or (c) are encapsulated within microparticles having a diameter of 25-100 microns.
- the container is constructed so as to enable mixing of the composition-of-matter with the liquid to generate a consumable suspension.
- composition-of-matter includes Bilobalide, Dihydromyricetin (Ampelosin) Ginkgolides, Puerarin, Limonene, Huperzine, Gingerols, Shogaols, Salicinic acid, Parthenolides, Proanthocyanidins, Curcumin, Piperin, Quercetin, Sesamin, Mangiferin, Co-Enzyme A and/or Amentoflavone,
- the Bilobalide, Dihydromyricetin (Ampelosin) Ginkgolides, Puerarin, Limonene, Huperzine, Gingerols, Shogaols, Salicin / Salicinic acid, Parthenolides, Proanthocyanidins, Curcumin, Piperin, Quercetin, Sesamin, Mangiferin, Co-Enzyme A and/or Amentoflavone, are microencapsulated.
- the microparticles include an encapsulant not soluble in acidic, enzyme-free liquid such as Zein and Shellac.
- microparticles further include Shellac, HPMC, glycerol and/or talcum.
- the microparticles include Shellac, and at least one compound selected from the group consisting of HPMC, HPMCP, Zein, PVA, Carbomer 940, Methyl Cellulose, Ethyl Cellulose, Alginate, Whey, Casein, a plasticizer, (such as PEG, Triethyl Citrate and Glycerol) and Talc.
- the microparticles include one or a combination of Prolamin proteins (Zein, Wheat, etc.), Shellac, fats (Coconut oil, Palm oil), Gelatin, Soy proteins, Pea proteins (Globulin), Vegetable proteins, Dextran, Maltodextrin, Cyclodextrin, Whey, Caseine, Guar gum, gum Arabic, Pectin, Amylose, Starches, Guar gum, Pectins, Chitosans, Alginates, Hydrogels, Polymethacrylates, Ethyl Cellulose, Methyl Cellulose.
- the present invention successfully addresses the shortcomings of the presently known configurations by providing a composition-of-matter that can be used to reduce or reverse both the physiological, motor and cognitive effects of alcohol on the body and/or deliver active ingredients to various regions of the GI in a timely manner.
- FIG. 1 illustrates a container suitable for delivery of the present composition.
- FIG. 2 illustrates non-encapsulated Glucose (left image) and Shellac-based encapsulated Glucose (right image).
- FIGs 3-6 illustrate the effect of the present composition on the motor and cognitive functions of an intoxicated subject.
- FIG. 7 is a graph showing release of Vitamin B2 in an aqueous medium having a pH of 1.1.
- FIGs. 8a-b schematically illustrate one embodiment of a two microparticle powder of the present invention showing the active ingredient core surrounded by one or more coating layers of each particle type.
- FIGs. 9a-c schematically illustrate one embodiment of a three microparticle powder of the present invention showing the active ingredient core surrounded by one or more coating layers of each particle type.
- FIGs. lOa-cb schematically illustrate another embodiment of a three microparticle powder of the present invention showing the active ingredient core surrounded by one or more coating layers of each particle type.
- FIGs. l la-c schematically illustrate another embodiment of a three microparticle powder of the present invention showing the active ingredient core surrounded by one or more coating layers of each particle type.
- the present invention is of a composition-of-matter which can be used to selectively deliver ingredients in the GI tract for the purpose of, for example, but not limited to, rapidly reversing or reducing the negative effects of alcohol consumption.
- taste masking can be effective in protection against a few hundred milligrams (at most) of bad tasting ingredients in a beverage or gel, but are ineffective when attempting to mask the bad tastes of ingredients at higher quantities.
- composition-of-matter that can be used to rapidly and timely remedy the variety of negative effects of alcohol consumption while addressing the above limitations of prior art products.
- composition-of matter of the present invention (also referred to herein as “the present composition") was formulated as a consumable liquid preparation and tested on intoxicated individuals.
- consumption of the present composition following alcohol consumption led to recovery of gastrointestinal motility temporarily impaired by alcohol consumption, accelerated blood alcohol metabolism, facilitated quicker recovery of motor, cognitive, information processing, memory, concentration, attention, decision making, impulse control, risk taking mitigation capabilities; and; improved negative physiological sensations (e.g. nausea, vomiting, headache, migraine, stomach pain, abdominal pain, tiredness, exhaustion, etc.) resulting from excess alcohol consumption.
- excess alcohol consumption refers to an amount of alcohol that when consumed results in negative cognitive and/or physiological effects on the user.
- alcohol intoxication or “excess alcohol consumption” refers to user's blood alcohol levels greater than 0.05%.
- composition of matter which includes the following active ingredients:
- a dietary supplement refers to a product taken orally that contains one or more ingredients that are intended to supplement an individual's diet and is not considered food (i.e. are not typically an energy source).
- Dietary supplements can be vitamins, minerals, herbs or other botanicals or extracts thereof, amino acids, or any other non-food substances capable of supplementing a diet.
- Carbohydrates which are typically used as an energy source, can also affect alcohol catabolism and are also optionally used in the present composition.
- composition-of-matter that includes (a) and (b), (a) and (c), (b) and (c) or (a)-(c) is preferred due to its combined effects.
- dietary supplements of (a), (b) or (c) are described hereinbelow.
- a composition of matter that includes dietary supplements encompassing (a), (b) and (c) is exemplified by Table 8.
- composition-of-matter which includes the following active ingredients:
- dietary supplements for reducing or abolishing the negative effects of alcohol on cognition, attention, concentration, memory, information processing, decision making, risk taking and/or impulse control, for example, supplements which exhibit antagonistic activity against GABA, dopamine, and serotonin and agonistic activity against glutamine;
- composition-of-matter that includes (a) and (b), (a) and (c) or (b) and (c) or (a), (b) and (c) is presently preferred due to its combined effects.
- a dietary supplement having antagonistic activity against GABA can be, for example, Bilobalide, Amentoflavone, Dihydromyricetin and Copper Glycinate Chelate.
- Bilobalide, Amentoflavone, Dihydromyricetin and Copper Glycinate Chelate exist in low concentrations in commercially available extracts of Ginkgo Biloba and Hovenia Dulcis, and its concentrations in extracts can be further elevated using commercially available extraction and purification technologies, i.e. Bilobalide, Amentoflavone, Dihydromyricetin can be sourced as a powdered extract from Ginkgo Biloba and Hovenia Dulcis while Copper Glycinate Chelate can be sourced as a Copper Glycinate Chelate from dietary supplement manufacturers.
- a dietary supplement having agonistic activity against glutamate can be, for example, L-Glutamate, L-aspartate, L-Alanine, Magnesium and Zinc.
- a dietary supplement having antagonistic activity against dopamine can be, for example, Amentoflavone, Adiantum venestum, Amaranthus virdis, Houttuynia cordata, Minthostachys mollis, Sargassum fusiforme and Usnea florida.
- Amentoflavone is present in different concentrations in Ginkgo Biloba extract. Extracts of Adiantum venestum, Amaranthus virdis, Houttuynia cordata, Minthostachys mollis, Sargassum fusiforme and Usnea florida are available from herbal extract manufacturers, primarily in China, India and South America.
- a dietary supplement having antagonistic activity against serotonin can be, for example, Bilobalide, Ginkgolides, Gingerols, Ginsenosides, Amentoflavone and Puerarin.
- Bilobalide, Amentoflavone and Ginkgolides are present in different concentrations in extracts of Ginkgo Biloba.
- Gingerols are present in different concentrations in extracts from Ginger
- Ginsenosides are present in different concentrations in extracts from differ varieties of Ginseng.
- Puerarin is present in different concentrations in extracts from Pueraria Lobata (Kudzu).
- Dietary supplements that can increase alcohol breakdown in the body or that reduce the level of toxic products of catabolism include, for example, an upregulator of ADH activity, upregulator of ALDHl activity, an upregulator of ALDH2 activity, an upregulator of Cyp2El activity, an upregulator of NAD+ activity, an acetaldehyde binding agent and an upregulator or activator of AMPK and/or SIRT.
- a dietary supplement capable of increasing alcohol catabolism can be, for example, a B Vitamin (e.g. Vitamin B l, 2, 3, 5, 6, 9 and/or 12), Pantethine, Vitamin E, TMG (Betaine), Choline salt, Zinc salt, SAMe, Nicotinamide, Folate/Folic acid and Alpha Lipoic Acid.
- B Vitamin e.g. Vitamin B l, 2, 3, 5, 6, 9 and/or 12
- Pantethine e.g. Vitamin B l, 2, 3, 5, 6, 9 and/or 12
- Vitamin E e.g. Vitamin E, TMG (Betaine)
- Choline salt Zinc salt
- SAMe Nicotinamide
- Folate/Folic acid e.g., Nicotinamide
- Alpha Lipoic Acid e.g., Alpha Lipoic Acid.
- Vitamin B6, Vitamin B 12 and Folate can also be used as a Methionine metabolism recovery agent. Such an agent can reduce liver injury and circulating Homocysteine levels.
- an acetaldehyde binding agent can be Proanthocyanidins or Cysteinylglycine, while an upregulator or activator of AMPK and/or SIRT can be Resveratrol, Sulforaphane, Fructose and Curcumin. These ingredients can be sourced from grapes, Broccoli and Curcuma Longa from dietary supplement and plant extract manufacturers around the globe.
- the present composition can also include a dietary supplement having anti-gastroparesis, antiemetic, analgesic and/or anti-inflammatory activities.
- an antiemetic agent acting as a serotonin (5-HT) antagonist which can be used in the present composition is Proanthocyanidins, Gingerols, Ginsenosides, Bilobalide or Ginkgolides, an anti-Gatroparesis agent acting as TRPV1 agonist and/or TRPA1 agonist can be Eriodictyol, Ursolic Acid, Capsaicin, alpha- Spinasterol, Gingerols, Shogaols, MSG and Kiwi extract. Eriodictyol is present in a variety of concentrations in extracts of Yerba Santa. Capsaicin is present in a variety of concentrations in extracts of Peppers.
- Ursolic acid is present in a variety of different concentrations in extracts of Berries and Basil.
- Gingerols are present in a variety of concentrations in extracts of Ginger.
- Alpha-Spinasterol is present in a variety of concentrations in extracts of Spinach.
- MSG is available from a variety of food additive manufacturers.
- the present composition can also include a lipid metabolism upregulating agent such as Creatine, Carnitine and Acetyl-L-Carnitine, as well as fish oil.
- a lipid metabolism upregulating agent such as Creatine, Carnitine and Acetyl-L-Carnitine, as well as fish oil.
- microcapsules encapsulating some of the ingredients in microcapsules with different coatings which isolate, rather than mask, the odors and the flavors of unpleasant tasting and smelling active ingredients.
- Such microcapsules also enable loading of an effective amount of active ingredients in a liquid unit of several hundreds of milliliters, or in a gel.
- microencapsulation was also selected so as to minimize or negate the gritty oral sensation often accompanied with consumption of suspended powders.
- Such gritty oral sensation of a beverage or a gel is a major obstacle to obtain a satisfactory positive consumption experience by the user.
- microencapsulation approaches were designed in order to selectively release different active ingredients (e.g. dietary supplements) throughout the GI tract (see the Examples section which follows for further description).
- active ingredients e.g. dietary supplements
- micro-encapsulation approaches can be used to encapsulate the dietary supplements of the present composition.
- examples of such approaches include encapsulating the dietary supplement raw materials with enteric and/or other encapsulating materials in a fluidized bed; spray-drying a mixture of a dietary supplement and enteric/encapsulant ingredients; and/or; freeze-drying a mixture spray- drying a mixture of a dietary supplement and enteric/encapsulant ingredients, and then grinding it to the desired final particle size/diameter.
- Dietary supplements which are preferably encapsulated include, but are not limited to, Alpha Lipoic Acid, Folic acid, Vitamin B l, Vitamin B2, Vitamin B3 (Nicotinamide), Vitamin B5/Pantethine, Vitamin B6, Vitamin B9 (Folate), Vitamin B 12, Vitamin D, Vitamin E, Glutathione, Carnitine/ Acetyl-L-Carnitine, Cysteine/N- Acetyl-Cysteine, Copper salt, Selenium salt, Magnesium salt, Zinc salt, Pyruvate salt, Co-enzyme A, Curcumin, Piperin, Quercetin, Resveratrol, Sesamin, Sulforaphane, Astaxanthin, Lemon (Limonene), Grape seed (Proanthocyanidins), Huperzia (Huperzine), Pueraria Lobata (Puerarin), Ginseng (Ginsenosides), Ginkgo Biloba (Bilobalide, Amentoflavone, G
- Tables 1-14 below provide several exemplary compositions formulated according to the teachings of the present invention.
- TMG Betaine
- Ginkgo Biloba (Bilobalide, Ginkgolide B) 300 600
- Ginger extract (Gingerols, Shogaols) 600 2,000
- TMG Betaine
- Ginkgo Biloba (Bilobalide, Ginkgolides) 300 600
- Ginger extract (Gingerols, Shogaols) 600 2,000
- Huperzia extract (Huperzine) 0.1 0.3
- Huperzia extract (Huperzine) 0.1 0.3
- composition-of-matter of the present invention can be formulated into any consumable product including gels, bars, snacks, shakes or drinks.
- the composition- of-matter of the present invention is optimized, and thus has significant benefits, when delivered in a water-containing formulation as a suspension or dispersion.
- Microencapsulation is a technology that is used to protect ingredients from degradation due to heat, moisture and/or presence of oxygen. Microencapsulation is also used to mask bad odors and tastes of ingredients and to enable controlled and targeted release/delivery of active ingredients in the GI tract.
- the present invention utilizes microencapsulation to isolate the taste and organoleptic characteristic (mouth sensation of particles) of various active ingredients and to deliver ingredients to different target sites in the GI tract.
- microencapsulated active ingredients are formulated as a powder which can be dispersed in a liquid beverage, shake or gelprior to consumption.
- the powder can be manufactured via spray drying with a three fluid or four fluid injectors incorporating more than a single fluid nozzle and capable of generating, in a single step, a core containing the active ingredient surrounded by at least one layer of a coating made from, for example, cellulose derivatives, proteins, methacrylate and other coating materials known in the food and pharmaceutical industry.
- Suitable spray drying technologies for use with the present invention include, but not limited to, 3- fluid spray drying, 4-fluid spray drying and ultrasonic dual-fluid or ultrasonic triple- fluid spray drying.
- the final microencapsulated product is a powder that is dispersed into, an acidic (2.0 - 4.0) liquid beverage, shake or a gel. Since the powder is insoluble and includes a high dose of active ingredients, a particle size optimizing dispersion, loading and minimization of a negative mouth sensation (organoleptic) was selected. The present inventors uncovered that a particle diameter for optimizing between particle loading and positive organoleptic sensation ranges between 20-100 microns, with 45 - 75 microns being the preferred size for the aforementioned application.
- an optimal diameter for a microparticle is between 25 - 100 microns and preferably between 45 - 75 microns.
- a diameter of 45 - 75 microns optimizes between minimum coating loading and a positive oral sensation (and thus an overall positive consumption experience) of a consumer.
- the ratio of core to coating (w/w) is between 1:10 to 20: 1, preferably in the range between 2:1 to 5: 1.
- microparticles are coated so as to be nearly insoluble in the aqueous environment of the consumed product, and in the mouth and esophagus of the individual consuming it.
- the powder composition can include several types of particles each offering a different release trigger and a different profile of release of the active ingredient core in the GI tract (stomach and below).
- Such selective release can be effected using different types of coating layers that are pH independent, and its disintegration is triggered in presence of enzymes, and augmented mechanical GI tract forces
- coatings that are insoluble in non-enzymatic acidic conditions can be fabricated from coating compositions based on Prolamin proteins (Zein, Wheat, etc.), Shellac, fats (Coconut oil, Palm oil, etc.), and any combination thereof. Such coatings can be used to selectively release the active core.
- Coatings dissolution in the presence of specific digestive enzymes can be based on Gelatin, Soy proteins, Pea proteins (Globulin), Vegetable proteins, fats, Starches, Dextran, Maltodextrin, Cyclodextrin, Whey and Caseine, and any combination thereof. Such coatings can be used to release the active core of the micro particle in the stomach.
- Coatings dissolution in the presence of a specific digestive enzyme of the small intestines include, but not limited to: Guar gum, gum Arabic, Pectin and Amylose, and any combination thereof. Such coatings can be used to release the active core of the microparticle in the small intestine.
- Coatings dissolution in the presence of enzyme of the colon include, but not limited to, Starches, Guar gum, Pectins, Chitosans, Alginates, Hydrogels, and any combination thereof. Such coatings can be used to release the active core of the microparticle in the Colon.
- Coatings dissolution under low pH conditions include, but not limited to, Polymethacrylates. Such coatings can be used to release the active core of the microparticle in the stomach.
- coatings that facilitate slow-release/controlled release, independent of enzymatic and pH conditions include, but not limited to, Ethyl Cellulose. Such coatings can be used for controlled release of an active core throughout the GI tract, water-soluble coatings include, but not limited to, Methyl Cellulose. Such coatings can be used in combination with the coatings described above in order to accelerate dissolution under the aforementioned conditions.
- the encapsulating layer of the microparticles can be non-uniform to allow selective dissolution of the microparticles and prolonged selective release of the active ingredient.
- the microparticles When the encapsulated microparticles are reconstructed into a liquid-based composition, the microparticles are preferably suspended in the liquid and are homogenously distributed therein (e.g. not floating at the surface of the liquid and not settling at the bottom of the container).
- the encapsulated microparticles are inert or materially inert in as far as taste and odor, or, incorporate a flavoring agent which masks or at the minimum materially masks the taste of the encapsulating coating layer.
- the encapsulation coating layer of the dietary supplement is designed not to dissolve or breakdown (e.g. to release its active core content) in the acidic non-enzymatic conditions of the liquid or the gel for at least 20 minutes. This enables the microparticles to survive as a suspension in the liquid/gel and pass through the mouth and esophagus without substantially releasing its contents.
- the composition begins to release its active ingredients (in a selective and controlled manner) in the stomach and/or the small intestines and/or in the colon, depending on the viscosity of the carrier, the properties of the coating layer and the (w/w) ratio between the encapsulation material and active ingredients.
- the present composition can include more than one type of a micro particle in a single powdered product.
- Different types of microparticles can include different cores (i.e. different active ingredient) and/or a different type of coating (facilitating selective release of more than one active ingredient).
- a single powdered dose unit can include:
- ingredient X (a) a microparticle facilitating rapid release of ingredient X (a dietary supplement) in the stomach
- each micro-particle has a core with at least one active ingredient.
- the active ingredient of the core can be mononuclear, multi-nuclear or incorporated in a slow- release or controlled release matrix.
- the core can also incorporate intestinal permeability enhancing agents.
- Each microparticle can include more than one coating layer, e.g. two or more coating layers each having a different dis solvability profile.
- a single coating layer is intended for use in beverages or other reconstructed compositions having a high-water content.
- a single layer of coating is designed to prevent the release of foul-tasting ingredients into the water for a time period sufficient for a common consumer to completely consume a 330 - 500 ml serving, e.g. 20-30 minutes.
- a single encapsulation layer incorporating at least 2 coating materials each having a different dis solvability profiles can be used to obtain stepwise release profiles.
- the microencapsulated active ingredients of the present invention can also be provided in a Ready-To-Drink (RTD) beverage.
- RTD Ready-To-Drink
- a first (and inner) encapsulation coating layer can control release as described above and at least one additional encapsulation layer can be used to seal the core and 1st encapsulation layer from the water in the RTD product.
- Such an outer encapsulation coating layer is designed for maximum sealing, and is rapidly breached under the enzymatic and/or mechanical grinding conditions of the stomach thereby exposing the inner encapsulation layer and its selective dissolution thereof.
- the outer (second) encapsulation coating layer can include materials which are insoluble in acidic, non-enzymatic conditions, but are rapidly dissolved/disintegrated under the enzymatic and/or mechanical grinding conditions of the stomach.
- materials include, but not limited to, Prolamin proteins (Zein, Wheat, etc.) and fats (Coconut oil, Palm oil) and any combinations thereof.
- Ginseng extract Ginseng Ginseng Ginseng Ginseng Ginseng Ginseng Ginseng Ginseng Ginseng Ginseng
- Shogaols Shogaols
- Shogaols Shogaols
- Shogaols Shogaols
- Shogaols Shogaols
- Parthenolides Parthenolides
- Ginger Ginger Ginger (Gingerols & (Gingerols & Shogaols) Shogaols)
- composition-of-matter of the present invention can be formulated as a ready-to-consume water-based drink, shake or gel which includes any of the above described ingredients as well as colorants, thickeners, flavoring agents, stabilizers and the like, or, as a powder containing the microencapsulated microparticles to be reconstituted in a drink or a gel prior to its consumption.
- a composition-of-matter formulated as a drink is also served in a container which maintains at least some of the active ingredients in powder form and isolated from the liquid carrier.
- an article of manufacturing which includes a container having two environmentally isolated compartments, one compartment for containing active ingredients in powder form, and the other for containing water and optionally dissolved components such as Fructose, Glucose, Betaine, Choline salt, and Creatine.
- Figure 1 illustrates one such container which is referred to herein as container 10.
- Container 10 is preferably shaped as elongated cylinder 25 cm in height, 6.5 cm in diameter and having a volume of 300-700 ml.
- Container 10 can be fabricated from, but not limited to, PET or Polypropylene using well known approaches.
- Container 10 includes two, environmentally-isolated, compartments (12 and 14) which are separated by partition 16.
- Container 10 further includes an opening 18 for accessing the contents of container 10, opening 18 can be sealed via a single use cover such as a pull tab, or a multi-use cover such as a screw cap.
- First compartment 12 is designed for containing the composition-of-matter described herein (e.g.
- Container 10 is designed such that partition 16 is breachable prior to unsealing of opening 18 thus enabling a user to mix the components of compartment 12 with the liquid of compartment 14 prior to consumption.
- Partition 16 can be breached via one of several mechanisms which can be functionally connected to a lid or cap covering opening 18.
- a screw cap covering opening 18 can be physically connected to partition 16 such that unscrewing of the screw cap breaches partition 18.
- the container can be vigorously shaken in order to dissolve and/or suspend the active ingredients in the water prior to consumption.
- the present invention provides a composition-of-matter which can be used to counteract the negative effects of alcohol consumption in a rapid and timely manner.
- composition of the present invention concurrently and timely addresses three key aspects of excess alcohol consumption by providing effective alcohol catabolism, improvements in motor, cognitive, attention, task switching, quality decision making and reduced risk taking behavior; and improvements in physiological sensations/feeling. Since the present composition can include relatively large quantities of water it also provides a beneficial rehydration effect along with large quantities of active ingredients.
- the present composition was designed for consumption following (e.g. after) alcohol uptake so as to not influence the desired positive effects of alcohol consumption from the consumer's subjective perception.
- consumption of the present composition prior to and/or concurrently with, alcohol consumption would prevent blood alcohol levels from peaking and thus would prevent or at least reduce motor and cognitive performance from degrading.
- Glucose with a pre-encapsulation diameter of 25 microns was encapsulated with a shellac -based composition.
- the shellac encapsulate included 65 grams of Shellac (SSB 57), 15 grams of Glycerin, 20 grams of HPMC (Vivapur E5LV), 3 grams of talcum and 600 grams of water.
- a fluidized bed was used for encapsulating the Glucose under the following conditions: Pressure blow back: 1.3 - 2.1 [bar]; Pressure pump feed: 3.4 [bar]; Spraying pressure: 2.5 [bar]; Airflow: 3.0 [M 3 per second]; Air temperature: 40 [Celsius].
- Figure 2 illustrates the non-encapsulated Glucose (left image) and Shellac- based encapsulated Glucose (right image).
- Encapsulated Glucose was placed under conditions simulating the stomach (pH 1.2) for 30 minutes, and then under conditions simulating the small intestines (pH 6.8).
- a D-Glucose UV Test (R-Biopharm) was used to analyze the quantity of Glucose released to the surrounding media. Following 30 minutes at pH 1.2 (stomach), 10% of the Glucose was released to the surrounding media. At pH 6.8 (intestines), all the remaining Glucose was released to the surrounding media following 40 minutes.
- the median alcohol catabolism rate was 0.019%/h in the composition-treated individuals vs. 0.011%/h in the control arm, a 48% advantage.
- the median alcohol catabolism rate in the composition study was 0.019%/h in the composition- treated individuals vs. 0.015%/h in the control arm, a 36% advantage.
- Each participant trained on each test for at least 3 hours to reach the highest level of self-proficiency and performance in order to avoid a learning curve during the study itself.
- each participant consumed an alcohol quantity calculated to bring his/her blood alcohol level to 0.1%, every 15 minutes, a blood alcohol level was measured for each participant (using the BACtrack S75 breathalyzer) which then performed the battery of cognitive tests from the Lumosity web site. At 45 minutes following the end of alcohol consumption, each participant consumed either the placebo composition or the present composition. (Participants were told the Placebo composition was an effective composition). Each session ended 3.5 hours following the completion of alcohol consumption.
- Tables 17 and 18 below present response time and normalized result (response time divided by accuracy %, generating a value representing response time in milliseconds at 100% accuracy) of placebo and present composition.
- Placebo Composition Diff Placebo Composition Diff.
- the Diff. represents the advantage (or disadvantage) of the response time in the Composition study vs. the Placebo study. (All values in the table are in Milliseconds). As can be viewed from the table above, there is a consistent advantage in response time in the Composition study vs. the Placebo study.
- the Diff. value represents the advantage (or disadvantage) of the response time in the Composition study vs. the Placebo study. (All values in the table are in Milliseconds representing response time @ theoretical 100% response accuracy). As can be viewed from the table above, except in a single measurement, there is a consistent advantage in response time in the Composition study vs. the Placebo study.
- Vitamin B2 was encapsulated with a prolamine-based coating.
- Prolamine proteins are water-insoluble, and edible (food-grade).
- a mini (lab-scale) spray dryer Buchi B-290 equipped with an advanced inert loop under nitrogen was used to encapsulate the Vitamin B2 with a 3 -fluid Buchi nozzle under the following conditions:
- Vitamin B2 20g of Vitamin B2 were dispersed in 80g of ethanol (or water)
- Feed rate core/shell 5ml/min /lOml/min
- the final product was collected and placed under condition simulating the enzyme-free acidic condition of the reconstructed beverage (only acid 1.1%).
- Vitamin B2 was tested in a spectrophotometer Perkin ELMER LAMBADA 25 at wavelength 268nanometer that is typical for Vitamin B2 absorbance.
- Powders having more than one microparticle type having more than one microparticle type
- composition-of-matter includes the two microparticle types shown in Figures 8a-b.
- the microparticle in Figure 8a has a core (A) with a diameter of 50 microns, and a coating layer (B) 5 microns thick, bringing the final diameter of the particle to 60 microns.
- the particle of Figure 8a includes a Ginger-extract active core surrounded by a zein-based coating layer.
- the coating layer of this particle is designed to be materially insoluble in non-enzymatic acidic conditions of the beverage, and to rapidly dissolve in the enzymatic conditions of the stomach.
- the particle of Figure 8b has a core (C) with a diameter of 55 microns, and a coating layer (D) 5 microns thick, bringing the final diameter of the particle to 65 microns.
- the particle is Figure 8b includes a Ginger extract active core surrounded by a coating layer of Shellac + HPMC.
- the coating layer of this particle is designed to be materially insoluble in the non-enzymatic acidic conditions of the beverage, materially insoluble in the acidic enzymatic conditions of the stomach, and to gradually dissolve in the enzymatic and pH conditions of the small intestines.
- a composition-of-matter including these two microparticle types enables rapid release of the Ginger extract (from the particle in Figure 8a) in the stomach thereby positively affecting local recovery of gastric motility through Ginger's 5-HT3 antagonistic properties, and to facilitate rapid absorption of Ginger constituents starting in the Duodenum for affecting brain receptor in the alleviation of nausea and vomiting.
- the later release of the Ginger extract (from the particle in Figure 8b) in the small intestines starting from the Jejunum facilitates the continuation of Ginger constituents absorption and maintenance of its anti-emetic brain properties
- composition-of-matter includes the three microparticle types shown in Figures 9a-c.
- the microparticle of Figure 9a has a core (E) with a diameter of 50 microns, and a coating layer (F) 10 microns thick, bringing the final diameter of the particle to 70 microns.
- the particle in Figure 9a includes Ginger extract and Piperin in the active core surrounded by a coating layer which includes Zein and a Cellulose derivative.
- the coating layer of this particle is designed to be materially insoluble in non- enzymatic acidic conditions of the beverage, and to rapidly dissolve in the enzymatic conditions of the stomach.
- the microparticle of Figure 9b has a core (G) with a diameter of 60 microns, and a coating layer (H) 7.5 microns thick, bringing the final diameter of the particle to 75 microns.
- the particle is Figure 9b includes Ginger extract and Piperin as the active core, surrounded by a coating layer which includes Zein and Shellac.
- the coating layer of this particle is designed to be materially insoluble in the non-enzymatic acidic conditions of a beverage, materially insoluble in the acidic enzymatic conditions of the stomach, and gradually dissolve in the enzymatic and pH conditions of the small intestines.
- the microparticle of Figure 9c has a core (I) with a diameter of 45 microns, and a coating layer (J) 7.5 microns thick, bringing the final diameter of the particle to 60 microns.
- the particle of Figure 9c includes a Ginger extract active core surrounded by a coating layer which includes cross-linked Alginate.
- the coating layer of this particle is designed to be materially insoluble in the non-enzymatic acidic conditions of the beverage, materially insoluble in the acidic enzymatic conditions of the stomach, materially insoluble in the enzymatic and pH conditions of the small intestines, and, gradually dissolve in the enzymatic and pH conditions of the Colon.
- a composition-of-matter including these three microparticle types enables rapid release of the Ginger extract and the Piperin (from the particle in Figure 9a) in the stomach positively affects local recovery of gastric motility through Ginger's 5- HT3 antagonistic properties and Piperin' s TRPV1 agonistic properties, and to facilitate rapid absorption of Ginger constituents starting in the Duodenum for affecting brain receptor in the alleviation of nausea and vomiting; and; to facilitate Piperin' s intestinal absorption enhancement properties.
- the later release of the Ginger extract and Piperin (from the particle in Figure 9b) in the small intestines starting from the Jejunum facilitates the continuation of Ginger constituents absorption and maintenance of its anti-emetic brain properties; and; Piperin' s continued enhancement of intestinal absorption,
- the targeted Colonic release of the Ginger extract (from the particle of Figure 9c) further facilitates its continued availability in the brain and anti-emetic action.
- this composition combines rapid recovery of gastric motility, enhancement of intestinal absorption and facilitation and maintenance of up to 8 hours of alleviating nausea and/or or vomiting sensations.
- composition-of-matter includes the three microparticle types shown in Figures lOa-c.
- the microparticle of Figure 10a has a core (K) with a diameter of 55 microns, and a coating layer (L) 5 microns thick, bringing the final diameter of the particle to 65 microns.
- the microparticle in Figure 10a includes a Mangiferin active core surrounded by a coating layer which includes fat and Cellulose.
- the coating layer of this particle is designed to be materially insoluble in non-enzymatic acidic conditions of the beverage, and to to rapidly dissolve in the enzymatic conditions of the stomach.
- the particle of Figure 10b has a core (M) with a diameter of 50 microns, and a coating layer (N) 5 microns thick, bringing the final diameter of the particle to 60 microns.
- the particle of Figure 10b includes Mangiferin and White Willow Bark extract (Salicin) as the active core surrounded by a coating layer including Ethyl Cellulose, MCG (Medium Chain Glycerides) and Oleic Acid.
- the coating layer of this particle is designed to be materially insoluble in the non-enzymatic acidic conditions of the beverage, materially insoluble in the acidic enzymatic conditions of the stomach, and to gradually dissolve in the enzymatic and pH conditions of the small intestines.
- the particle of Figure 10c has a core (O) with a diameter of 45 microns, and a coating layer (P) 5 microns thick, bringing the final diameter of the particle to 55 microns.
- the particle of Figure 10c includes White Willow Bark extract (Salicin) as the active core, surrounded by a coating layer including Alginate and Starch.
- the coating layer of this particle is designed to be materially insoluble in the non- enzymatic acidic conditions of the beverage, materially insoluble in the acidic enzymatic conditions of the stomach, materially insoluble in the enzymatic and pH conditions of the small intestines, and, gradually dissolve in the enzymatic and pH conditions of the Colon.
- a composition-of-matter including these three microparticle types enables rapid release of Mangiferin (from the microparticle in Figure 10c) in the stomach positively affecting local recovery of gastric motility of the stomach through Mangiferin's 5-HT4 agonistic properties and facilitating rapid activation of intestinal 5-HT4 receptors by Mangiferin starting in the Duodenum.
- composition-of-matter was designed for a shelf life of over 3 months after reconstruction into an orally-deliverable gel.
- This composition is manufactured using a spray dryer with a 4-fluid injector, where 3 of the 4 channels are fed with fluids and/or melted fat, and single channel is utilizing air or Nitrogen, as applicable.
- composition-of-matter includes the three microparticle types shown in Figures l la-c.
- the microparticle of Figure 11a has a core (Q) with a diameter of 40 microns, a first and inner coating layer (R) 10 microns thick, bringing the diameter of the particle to 60 microns and a second and outer coating layer (S) 5 microns thick, bringing the final diameter of the particle to 70 microns.
- the microparticle of Figure 11a includes Ginger extract and Piperin as the active core surrounded by an inner coating layer including Zein and a Cellulose derivative, and an outer coating layer including Gelatin and fat (Carnauba, Stearic acid, Sunflower).
- the outer coating layer improves the impermeability of the particle to acidic water and/or dissolution in acidic water-containing gel (thus providing longer shelf-life), but is quickly dissolvable in the enzymatic conditions of the stomach.
- the inner coating layer of this particle is designed to be materially insoluble in non- enzymatic acidic conditions of the gel, and to rapidly dissolve in the enzymatic conditions of the stomach.
- the microparticle of Figure 1 lb has a core (T) with a diameter of 50 microns, a first and inner coating layer (U) 10 microns thick, bringing the diameter of the particle to 60 microns and a second and outer coating layer (V) 5 microns thick, bringing the final diameter of the particle to 70 microns.
- the microparticle of Figure l ib includes Ginger extract and Piperin as the active core surrounded by an inner coating layer including Zein and Shellac, and an outer coating layer including Gelatin and fat (Carnauba, Stearic acid, Sunflower).
- the outer coating layer improves the impermeability of the particle to acidic water and/or dissolution in acidic water-containing gel (thus providing longer shelf-life), but is quickly dissolvable in the enzymatic conditions of the stomach.
- the inner coating layer of this particle is designed to be materially insoluble in the non-enzymatic acidic conditions of the gel, materially insoluble in the acidic enzymatic conditions of the stomach, and to gradually dissolve in the enzymatic and pH conditions of the small intestines.
- the microparticle of Figure 11c has a core (W) with a diameter of 45 microns, a first and inner coating layer (X) 5 microns thick, bringing the diameter of the particle to 55 microns and a second and outer coating layer (Y) 5 microns thick, bringing the final diameter of the particle to 65 microns.
- the microparticle of Figure 11c includes a Ginger extract active core surrounded by an inner coating layer of cross-linked Alginate and an outer coating layer of Gelatin and fat (Carnauba, Stearic acid, Sunflower).
- the outer coating layer improves the impermeability of the particle to acidic water and/or dissolution in acidic water-containing gel (thus providing longer shelf -life), but is quickly dissolvable in the enzymatic conditions of the stomach.
- the inner coating layer of this particle is designed to be materially insoluble in the non-enzymatic acidic conditions of the gel, materially insoluble in the acidic enzymatic conditions of the stomach, materially insoluble in the enzymatic and pH conditions of the small intestines, and gradually dissolve in the enzymatic and pH conditions of the Colon.
- a composition-of-matter including these three microparticle types enables rapid release of the Ginger extract and the Piperin (from the microparticle of Figure 11a) in the stomach positively affects local recovery of gastric motility through Ginger's 5-HT3 antagonistic properties and Piperin's TRPV1 agonistic properties, and facilitating rapid absorption of Ginger constituents starting in the Duodenum for affecting brain receptor in the alleviation of nausea and vomiting and facilitating Piperin's intestinal absorption enhancement properties.
- this composition with its 3 coating implementations, combines rapid recovery of gastric motility, enhancement of intestinal absorption and facilitation and maintenance of up to 8 hours of alleviating nausea and/or or vomiting sensations.
Abstract
A composition-of-matter is provided. The present composition includes dietary supplements capable of reducing or reversing the negative effects of alcohol on motor and cognition, dietary supplements having anti-gastroparesis, antiemetic, analgesic and anti-inflammatory activities and/or dietary supplements capable of increasing alcohol catabolism and decreasing the level of toxic products of alcohol catabolism.
Description
COMPOSITIONS AND METHODS FOR SELECTIVE GI TRACT DELIVERY
FIELD AND BACKGROUND OF THE INVENTION
The present invention relates to compositions and methods of using same for selective delivery of active ingredients in the GI tract. Embodiments of the present invention relate to a liquid (aqueous) preparation incorporating soluble and/or suspended bioactive ingredients for remedying the effects of excessive alcohol consumption.
Alcohol is the most popular legal intoxicant around the globe. The current global market for alcoholic beverages is in excess of $900B a year. In Europe, for example, the average daily consumption of alcohol per person is in excess of 40 grams of pure alcohol. This average daily alcohol consumption quantity is comparable to the consumption of 3 beers.
Alcohol consumption intoxicates the human body and results in a wide variety of short term and not infrequently long term negative side effects and outcomes. The first metabolic intermediate generated through alcohol metabolism in the human body is acetaldehyde, a toxic compound even at very low concentrations. Therefore, in order to avoid irreversible short term health damages and optionally death, the rate of alcohol metabolism by the human body is limited by its ability to metabolize and remove blood and/or cell-attached and/or tissue-attached acetaldehyde. As a result, the rate of blood alcohol metabolism is quite slow, typically ranging between 0.03 - 0.15 gram percent per hour by occasional alcohol consumers, and up to 0.15 - 0.25 gram percent per hour by binge and alcoholic drinkers.
Alcohol significantly impairs both motor and cognitive performance. The most critical activity impaired by blood alcohol and blood acetaldehyde is driving, which is materially negatively affected by the effect of alcohol and acetaldehyde on the brain, resulting in reduced cognitive and motor performance, and further accompanied by the impairment of judgment and sliding into reckless behavior and undesired risk taking. Yet, only lately, a series of clinical research studies found out, that while motor function following alcohol consumption is more quickly restored when BAC level is on the decreasing slope, cognitive performance and maintenance of reckless behavior/risk taking significantly lags behind it. This means, that the alcohol
intoxicated individual subjectively feels recovered from the intoxicating effects of excess alcohol consumption, where in reality, the impaired cognitive judgment and response functions are still far from normal. This phenomena is true in many cases where the blood alcohol levels are already within legal limits in many countries around the globe. This gap between motor performance recovery and cognitive (and judgment) performance recovery is a major reason why cognitive function' impaired drinkers make a decision to enter their car and drive, leading - in an ineligible number of events - to severe and not infrequently - lethal accidents.
Several products in the market attempt to resolve some of the negative outcomes of excess alcohol consumption. These products are frequently powder-based products, which need to be reconstructed into liquid (typically water) prior to its consumption. Examples of such products are Sobrietol™, Party Smart™, Drinkin' Mate™, NOHO™, RU-21™, Hangover Hater™, AL-neutralizer™, Hangover Joe's, etc. The target of most products on the market is to alleviate the morning-after hangover symptoms. With very similar compositions - mainly B + C vitamins, minerals and amino acids, these products target the replenishment of the body of the depletion of these important compounds during excess blood alcohol metabolism. Sobrietol™ takes a different approach, by incorporating alcohol metabolizing enzymes, which target the decomposition of the consumed alcohol in the stomach and intestines, and thus reduce the absorption of alcohol into systemic circulation. Naturally, a person needs to consume Sobrietol prior to alcohol consumption, in order for the Sobrietol™ product to demonstrate some level of efficacy. A third approach is taken by Party Smart™. This product incorporates a number of plant extracts, which claim targeting the protection of liver damage through anti-oxidant activities and through affecting increased alcohol metabolizing enzymes' activity. Similar to the other above-mentioned products, Party Smart™ needs to be consumed prior to alcohol consumption. Human data demonstrating the impact of these products on hangover and blood alcohol is very limited, or demonstrate very limited efficacy.
Therefore, there remains a need for a composition-of-matter that can be used to remedy the negative effects of excess alcohol consumption.
SUMMARY OF THE INVENTION
According to one aspect of the present invention there is provided a composition-of-matter comprising at least two types of microparticles each formed from an active ingredient core encapsulated by at least one coating material, the at least two types of said microparticles being differentiated by the active ingredient or the at least one coating material.
According to further features in preferred embodiments of the invention described below each of the at least two types of said microparticles is capable of releasing the active ingredient at a different region of a GI tract.
According to still further features in the described preferred embodiments the microparticles have a diameter of 25-100 microns.
According to still further features in the described preferred embodiments the active ingredient core of the composition-of-matter comprises at least one of: (a) dietary supplements having cognitive and motor function; (b) dietary supplements having anti-gastroparesis, antiemetic, analgesic and anti-inflammatory activities; and/or (c) dietary supplements being capable of increasing alcohol catabolism.
According to still further features in the described preferred embodiments the composition-of-matter comprises (a) and (b), (b) and (c) or (a) and (c).
According to still further features in the described preferred embodiments at least some of the dietary supplements of (a)-(c) are encapsulated within microparticles.
According to still further features in the described preferred embodiments the composition-of-matter is formulated as a beverage.
According to still further features in the described preferred embodiments the composition-of-matter is formulated as a gel.
According to still further features in the described preferred embodiments a pH of the beverage or the gel is 2.4-3.5.
According to still further features in the described preferred embodiments, the beverage or gel do not contain enzymes.
According to further features in the described embodiments, the dietary supplements having cognitive and motor function are selected from the group having antagonistic activity against GABA, Adenosine Al, AchE, Dopamine Dl, Dopamine D2, Dopamine D3, 5-HT1A, 5-HT2 and 5HT3; and; agonistic activity against Glutamate, Adenosine A2A, 5-HT1B and 5-HT4
According to still further features in the described preferred embodiments the dietary supplement having antagonistic activity against GABA is selected from the group consisting of Bilobalide, Ginkgolides (A, B & C), Puerarin, Resveratrol, Quercetin, Curcumin, Caffeine, Theophylline, Amentoflavone, Dihydromyricetin and Copper Glycinate Chelate.
According to still further features in the described preferred embodiments the dietary supplement having antagonistic activity against Adenosine Al is selected from the group consisting of Caffeine and Theophylline.
According to still further features in the described preferred embodiments the dietary supplement having antagonistic activity against AchE is selected from the group consisting of Huperzine A and Rosmarinic acid.
According to still further features in the described preferred embodiments the dietary supplement having antagonistic activity against Dopamine Dl is selected from the group consisting of Ginkgolide A, Parthenolides, Salicin, Eriodictyol, N-Acetyl- Cysteine, Magnesium, Zinc, Amentoflavone, Adiantum venestum, Amaranthus virdis, Houttuynia cordata, Minthostachys mollis, Sargassum fusiforme and Usnea florida.
According to still further features in the described preferred embodiments the dietary supplement having antagonistic activity against Dopamine D2 is selected from the group consisting of Limonene, Parthenolides, Eriodictyol, N-Acetyl-Cysteine, Alpha Lipoic Acid, Magnesium, Zinc, Amentoflavone, Adiantum venestum, Amaranthus virdis, Houttuynia cordata, Minthostachys mollis, Sargassum fusiforme and Usnea florida
According to still further features in the described preferred embodiments the dietary supplement having antagonistic activity against Dopamine D3 is selected from the group consisting of Ginkgolide C, Parthenolides, Eriodictyol, N-Acetyl-Cysteine, Magnesium, Zinc, Amentoflavone, Adiantum venestum, Amaranthus virdis, Houttuynia cordata, Minthostachys mollis, Sargassum fusiforme and Usnea florida.
According to still further features in the described preferred embodiments the dietary supplement having antagonistic activity against 5-HT1A is selected from the group consisting of Limonene, Proanthocyanidins and Zinc.
According to still further features in the described preferred embodiments the dietary supplement having antagonistic activity against 5-HT2 is selected from the
group consisting of Puerarin, Limonene, Quercetin, Parthenolides, Salicin, Sulforaphane, Proanthocyanidins and Menthol.
According to still further features in the described preferred embodiments the dietary supplement having antagonistic activity against 5-HT3 is selected from the group consisting of Bilobalide, Ginkgolide B, Quercetin, Gingerols, Shogaols, Parthenolides, Proanthocyanidins and Menthol.
According to still further features in the described preferred embodiments the dietary supplement having agonistic activity against Glutamate is selected from the group consisting of Bilobalide, Huperzine A, N-Acetyl-Cysteine, Acetyl-L-Carnitine, Glutamic acid, Glycine, L-Glutamate, L-aspartate, L- Alanine, Magnesium and Zinc.
According to still further features in the described preferred embodiments the dietary supplement having agonistic activity against Adenosine A2A is selected from the group consisting of Polygala Limonene, Tenuifolia, Acorus gramineus, and Poria cocos.
According to still further features in the described preferred embodiments the dietary supplement having agonistic activity against 5-HT1B is selected from the group consisting of Limonene, Gingerols, Shogaols, Sulforaphane, Betaine and N- Acetyl-Cysteine.
According to still further features in the described preferred embodiments the dietary supplement having agonistic activity against 5-HT4 is selected from the group consisting of Mangiferin.
According to further features in the described embodiments, the dietary supplements having anti-gastroparesis, antiemetic, analgesic and anti-inflammatory activities are selected from the group having antagonistic activity against Dopamine Dl, Dopamine D2, Dopamine D3, 5-HT3; and; agonistic activity against CB 1, CB2, TRPA1, TRPV1, 5-HT4, and; further activity providing COX inhibition / suppression, Prostaglandin synthesis suppression, Histamine inhibition, AMPK upregulation and vascular spasm reduction.
According to still further features in the described preferred embodiments the dietary supplement having agonistic activity against CB 1 and/or CB2 is selected from the group consisting of Cannabidiol and Falcarinol,
According to still further features in the described preferred embodiments the dietary supplement having agonistic activity against TRPA1 is selected from the group consisting of Shogaols, Zinc, Mustard oil and Carnosol.
According to still further features in the described preferred embodiments the dietary supplement having agonistic activity against TRPV1 is selected from the group consisting of Shogaols, Piperin, Magnesium, Omega-3, Achinacea, Carvone and Camphor.
According to still further features in the described preferred embodiments the dietary supplement having Cox inhibitor activity is selected from the group consisting of Curcumin, Thunder God Vine, Resveratrol, Quercetin, Kaempferol, Pycogenol, Parthenolides, EGCG, Ursolic acid, Berberine and Ginsenosides.
According to still further features in the described preferred embodiments the dietary supplement having Prostaglandin inhibitor activity is selected from the group consisting of Gingerols, Shogaols, Salicin and Hesperidin.
According to still further features in the described preferred embodiments the dietary supplement having Histamine inhibitor activity is selected from the group consisting of Quercetin, Vitamin C, Mangosteen, and Butterbur.
According to further features in the described embodiments, the dietary supplements capable of increasing alcohol catabolism are selected from the group consisting of alcohol and acetaldehyde catabolism co-factors, acetate catabolism co- factors, an upregulator of ADH activity, an upregulator of ALDH activity, an upregulator of Cyp2El activity, an upregulator of NAD+ activity, an acetaldehyde binding agent, an upregulator or activator of AMPK and/or SIRT; and a down- regulator of CD38, CD157 and/or PARP.
According to still further features in the described preferred embodiments the dietary supplement is an Alcohol and/or Acetaldehyde catabolism co-factor selected from the group consisting of B Vitamins: 1,2,3,5,6,9 and 12, Pantethine, Vitamin E, TMG (Betaine), Choline salt, Zinc salt, SAMe, Nicotinamide, Folate / Folic acid and Alpha Lipoic Acid.
According to still further features in the described preferred embodiments the dietary supplement is an Acetate catabolism co-factor such as Co-enzyme A.
According to still further features in the described preferred embodiments the dietary supplement is an Acetaldehyde binding agent selected from the group consisting of Proanthocyanidins and Cysteinylglycine.
According to still further features in the described preferred embodiments the dietary supplement is an upregulator of ADH activity selected from the group consisting of Magnesium and Zinc.
According to still further features in the described preferred embodiments the dietary supplement is an upregulator of ALDH activity selected from the group consisting of Sulforaphane, N-Acetyl-Cysteine and Alpha Lipoic Acid.
According to still further features in the described preferred embodiments the dietary supplement is an upregulator of NAD+ activity selected from the group consisting of Resveratrol, Quercetin, Caffeine, Theophylline, Betaine / TMG, Choline, N-Acetyl-Cysteine, Alpha Lipoic Acid, Acetyl-L-Carnitine, Pyruvate, Co-Enzyme A and Fructose.
According to still further features in the described preferred embodiments the dietary supplement is an upregulator of AMPK activity selected from the group consisting of Bilobalide, Puerarin, Resveratrol, Quercetin, Shogaols, Salicin, Sulforaphane, Menthol, Betaine / TMG, Choline, Alpha Lipoic Acid and Acetyl-L- Carnitine.
According to still further features in the described preferred embodiments the dietary supplement is an upregulator of SIRT activity selected from the group consisting of Resveratrol, Quercetin, Curcumin, Sulforaphane, N-Acetyl-Cysteine and Fructose.
According to still further features in the described preferred embodiments the dietary supplement is a down-regulator of CD38 and/or CD 157 activity selected from the group consisting of Quercetin.
According to still further features in the described preferred embodiments the dietary supplement is a down-regulator of PARP activity selected from the group consisting of Quercetin, Caffeine, Theophylline, Curcumin, Sulforaphane, Eriodictyol, Betaine / TMG, N- Acetyl-Cysteine and Pyruvate.
According to another aspect of the present invention there is provided an article of manufacturing comprising a container having two environmentally isolated compartments, a first compartment including the composition-of-matter of claim 1
and, a second compartment including a liquid, wherein at least a portion of the dietary supplements of (a), (b) and/or (c) are encapsulated within microparticles having a diameter of 25-100 microns.
According to still further features in the described preferred embodiments the container is constructed so as to enable mixing of the composition-of-matter with the liquid to generate a consumable suspension.
According to still further features in the described preferred embodiments the composition-of-matter includes Bilobalide, Dihydromyricetin (Ampelosin) Ginkgolides, Puerarin, Limonene, Huperzine, Gingerols, Shogaols, Salicinic acid, Parthenolides, Proanthocyanidins, Curcumin, Piperin, Quercetin, Sesamin, Mangiferin, Co-Enzyme A and/or Amentoflavone,
According to still further features in the described preferred embodiments the Bilobalide, Dihydromyricetin (Ampelosin) Ginkgolides, Puerarin, Limonene, Huperzine, Gingerols, Shogaols, Salicin / Salicinic acid, Parthenolides, Proanthocyanidins, Curcumin, Piperin, Quercetin, Sesamin, Mangiferin, Co-Enzyme A and/or Amentoflavone, are microencapsulated.
According to still further features in the described preferred embodiments the microparticles include an encapsulant not soluble in acidic, enzyme-free liquid such as Zein and Shellac.
According to still further features in the described preferred embodiments the microparticles further include Shellac, HPMC, glycerol and/or talcum.
According to still further features in the described preferred embodiments the microparticles include Shellac, and at least one compound selected from the group consisting of HPMC, HPMCP, Zein, PVA, Carbomer 940, Methyl Cellulose, Ethyl Cellulose, Alginate, Whey, Casein, a plasticizer, (such as PEG, Triethyl Citrate and Glycerol) and Talc.
According to still further features in the described preferred embodiments the microparticles include one or a combination of Prolamin proteins (Zein, Wheat, etc.), Shellac, fats (Coconut oil, Palm oil), Gelatin, Soy proteins, Pea proteins (Globulin), Vegetable proteins, Dextran, Maltodextrin, Cyclodextrin, Whey, Caseine, Guar gum, gum Arabic, Pectin, Amylose, Starches, Guar gum, Pectins, Chitosans, Alginates, Hydrogels, Polymethacrylates, Ethyl Cellulose, Methyl Cellulose.
The present invention successfully addresses the shortcomings of the presently known configurations by providing a composition-of-matter that can be used to reduce or reverse both the physiological, motor and cognitive effects of alcohol on the body and/or deliver active ingredients to various regions of the GI in a timely manner.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
In the drawings:
FIG. 1 illustrates a container suitable for delivery of the present composition.
FIG. 2 illustrates non-encapsulated Glucose (left image) and Shellac-based encapsulated Glucose (right image).
FIGs 3-6 illustrate the effect of the present composition on the motor and cognitive functions of an intoxicated subject.
FIG. 7 is a graph showing release of Vitamin B2 in an aqueous medium having a pH of 1.1.
FIGs. 8a-b schematically illustrate one embodiment of a two microparticle powder of the present invention showing the active ingredient core surrounded by one or more coating layers of each particle type.
FIGs. 9a-c schematically illustrate one embodiment of a three microparticle powder of the present invention showing the active ingredient core surrounded by one or more coating layers of each particle type.
FIGs. lOa-cb schematically illustrate another embodiment of a three microparticle powder of the present invention showing the active ingredient core surrounded by one or more coating layers of each particle type.
FIGs. l la-c schematically illustrate another embodiment of a three microparticle powder of the present invention showing the active ingredient core surrounded by one or more coating layers of each particle type.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention is of a composition-of-matter which can be used to selectively deliver ingredients in the GI tract for the purpose of, for example, but not limited to, rapidly reversing or reducing the negative effects of alcohol consumption.
The principles and operation of the present invention may be better understood with reference to the drawings and accompanying descriptions and examples.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.
Several products attempt to provide relief from, or reduce the negative effects of alcohol consumption. Such products are unpopular with drinkers and do not provide the benefits claimed at least for the following reasons:
(i) people drink alcohol to enjoy its actual and/or perceived positive impacts: improved mood, social openness, etc. A product which is consumed prior to and/or concurrently with alcohol consumption, can reduce the desired effects of alcohol sought by drinkers.
(ii) due to solubility and bad taste issues, such products incorporate relatively small quantities (w/v or v/v) of active ingredients; such small quantities are not effective in timely coping with the dozens of milliliters of circulating pure alcohol and its metabolites.
(iii) compounds (vitamins, minerals, amino acids, etc.) depleted in the body during alcohol metabolism are water soluble (hydrophilic) and water insoluble (hydrophobic). Thus, replenishment of such compounds requires that both types of ingredients are present in a single liquid medium (for ensuring very quick availability in the GI tract). This results in a less than favorable consumption experience since some of the ingredients are present as a bad-tasting suspension;
(iv) some of the key compounds depleted from the body during alcohol metabolism are poorly absorbed through the intestines. As such, very little quantities of such ingredients are naturally absorbed into the blood stream from presently available products;
(v) some ingredients suitable for use in such products have an unpleasant taste and as such are often not used;
(vi) existing products do not address the negative effects of alcohol and its metabolites on cognitive functions such as information processing, memory, attention, concentration, decision making / impulse control, risk taking, and/or motor functions;
(vii) limited human data publically available for existing products demonstrates an alcohol metabolism acceleration of 5% - 15%. This is relatively a low and insufficient acceleration outcome from a consumer standpoint.
(viii) existing products do not address the gastroparesis effects of alcohol consumption, which prevent or at the minimum significantly slow-down the passage of replenishing ingredients past the stomach and its absorption starting in the Duodenum.
(ix) Existing products do not address, sufficiently early, the negative physiological sensations resulting from alcohol consumption (e.g. nausea / vomiting, headache / migraine, stomach pain / abdominal pain, fatigue, etc.). As a result, instead of preventing the initiation of these symptoms, existing products target the reduction of symptoms after they have already occurred (typically the morning after).
(x) technologies for minimizing unpleasant taste primarily focus on taste masking. Taste masking can be effective in protection against a few hundred
milligrams (at most) of bad tasting ingredients in a beverage or gel, but are ineffective when attempting to mask the bad tastes of ingredients at higher quantities.
While reducing the present invention to practice, the present inventors formulated a composition-of-matter that can be used to rapidly and timely remedy the variety of negative effects of alcohol consumption while addressing the above limitations of prior art products.
The present composition provides the following advantages:
(a) it can accelerate alcohol metabolism in the body by as much as 100%;
(b) it can effectively reduce the effect of alcohol on the brain, specifically the negative effects of alcohol on information processing, memory, cognition, decision making / impulse control, risk taking and motor performance;
(c) it can reduce the effect of alcohol on the body, specifically the negative effects of alcohol on physiology (e.g. nausea, vomiting, fatigue, headache, migraine, light headedness, stomach pain, abdominal pain, etc.);
(d) it can be consumed anytime following alcohol consumption while not negatively affecting the desired effect of alcohol as perceived by the consumer;
(e) it can provide effective quantities of the active ingredients in a relatively small volume of liquid, having a positive effect on the rate of response and effectiveness;
(f) it does not have an unpleasant taste or odor, even when the amount of ingredients is significant (between 10 - 100 grams);
(g) it can improve some of the negative effects of alcohol as early as 5 - 10 minutes post the beginning of consumption;
(h) it can prolong the duration of significant prevention or improvement of the alcohol intoxication symptoms to 2 - 8 hours post a single consumption;
(i) it is effective in treating both low blood alcohol levels (e.g. 0.020% - 0.050%) as well as high blood alcohol levels (e.g. 0.050% - 0.200%);
(j) It is effective in recovering gastrointestinal motility temporarily impaired by alcohol consumption;
(k) It is effective in recovering capabilities relating to information processing, memory, attention, decision making, impulse control, risk taking and motor performance impaired by alcohol consumption.
An embodiment of the composition-of matter of the present invention (also referred to herein as "the present composition") was formulated as a consumable liquid preparation and tested on intoxicated individuals. As is described in the Examples section which follows, consumption of the present composition following alcohol consumption led to recovery of gastrointestinal motility temporarily impaired by alcohol consumption, accelerated blood alcohol metabolism, facilitated quicker recovery of motor, cognitive, information processing, memory, concentration, attention, decision making, impulse control, risk taking mitigation capabilities; and; improved negative physiological sensations (e.g. nausea, vomiting, headache, migraine, stomach pain, abdominal pain, tiredness, exhaustion, etc.) resulting from excess alcohol consumption.
As used herein, excess alcohol consumption refers to an amount of alcohol that when consumed results in negative cognitive and/or physiological effects on the user. As used herein, "alcohol intoxication" or "excess alcohol consumption" refers to user's blood alcohol levels greater than 0.05%.
Thus, according to one aspect of the present invention there is provided a composition of matter which includes the following active ingredients:
(a) dietary supplements affecting motor and, cognitive performance;
(b) dietary supplements having anti-gastroparesis, antiemetic, analgesic and anti-inflammatory activities; and/or
(c) dietary supplements being capable of increasing alcohol catabolism.
As used herein, a dietary supplement refers to a product taken orally that contains one or more ingredients that are intended to supplement an individual's diet and is not considered food (i.e. are not typically an energy source). Dietary supplements can be vitamins, minerals, herbs or other botanicals or extracts thereof, amino acids, or any other non-food substances capable of supplementing a diet. Carbohydrates which are typically used as an energy source, can also affect alcohol catabolism and are also optionally used in the present composition.
Although any of the above (a)-(c) can individually provide a beneficial effect on individuals under alcohol influence or intoxicated individuals, it will be appreciated that a composition-of-matter that includes (a) and (b), (a) and (c), (b) and (c) or (a)-(c) is preferred due to its combined effects.
Examples of dietary supplements of (a), (b) or (c) are described hereinbelow. A composition of matter that includes dietary supplements encompassing (a), (b) and (c) is exemplified by Table 8.
According to another aspect of the present invention there is provided a composition-of-matter which includes the following active ingredients:
(a) dietary supplements for reducing or abolishing the negative effects of alcohol on cognition, attention, concentration, memory, information processing, decision making, risk taking and/or impulse control, for example, supplements which exhibit antagonistic activity against GABA, dopamine, and serotonin and agonistic activity against glutamine;
(b) dietary supplements having free-radical scavenging, anti-gastroparesis, antiemetic, analgesic and anti-inflammatory activities; and/or
(c) dietary supplements capable of increasing alcohol catabolism and/or reducing the levels of toxic products resulting from alcohol catabolism.
Although any of the above (a)-(c) can individually provide a beneficial effect on individuals under alcohol influence or intoxicated individuals, it will be appreciated that a composition-of-matter that includes (a) and (b), (a) and (c) or (b) and (c) or (a), (b) and (c) is presently preferred due to its combined effects.
A dietary supplement having antagonistic activity against GABA can be, for example, Bilobalide, Amentoflavone, Dihydromyricetin and Copper Glycinate Chelate. These exist in low concentrations in commercially available extracts of Ginkgo Biloba and Hovenia Dulcis, and its concentrations in extracts can be further elevated using commercially available extraction and purification technologies, i.e. Bilobalide, Amentoflavone, Dihydromyricetin can be sourced as a powdered extract from Ginkgo Biloba and Hovenia Dulcis while Copper Glycinate Chelate can be sourced as a Copper Glycinate Chelate from dietary supplement manufacturers.
A dietary supplement having agonistic activity against glutamate can be, for example, L-Glutamate, L-aspartate, L-Alanine, Magnesium and Zinc.
A dietary supplement having antagonistic activity against dopamine can be, for example, Amentoflavone, Adiantum venestum, Amaranthus virdis, Houttuynia cordata, Minthostachys mollis, Sargassum fusiforme and Usnea florida. Amentoflavone is present in different concentrations in Ginkgo Biloba extract. Extracts of Adiantum venestum, Amaranthus virdis, Houttuynia cordata,
Minthostachys mollis, Sargassum fusiforme and Usnea florida are available from herbal extract manufacturers, primarily in China, India and South America.
A dietary supplement having antagonistic activity against serotonin can be, for example, Bilobalide, Ginkgolides, Gingerols, Ginsenosides, Amentoflavone and Puerarin. Bilobalide, Amentoflavone and Ginkgolides are present in different concentrations in extracts of Ginkgo Biloba. Gingerols are present in different concentrations in extracts from Ginger , Ginsenosides are present in different concentrations in extracts from differ varieties of Ginseng. Puerarin is present in different concentrations in extracts from Pueraria Lobata (Kudzu).
Dietary supplements that can increase alcohol breakdown in the body or that reduce the level of toxic products of catabolism include, for example, an upregulator of ADH activity, upregulator of ALDHl activity, an upregulator of ALDH2 activity, an upregulator of Cyp2El activity, an upregulator of NAD+ activity, an acetaldehyde binding agent and an upregulator or activator of AMPK and/or SIRT.
A dietary supplement capable of increasing alcohol catabolism can be, for example, a B Vitamin (e.g. Vitamin B l, 2, 3, 5, 6, 9 and/or 12), Pantethine, Vitamin E, TMG (Betaine), Choline salt, Zinc salt, SAMe, Nicotinamide, Folate/Folic acid and Alpha Lipoic Acid.
Vitamin B6, Vitamin B 12 and Folate can also be used as a Methionine metabolism recovery agent. Such an agent can reduce liver injury and circulating Homocysteine levels.
An example of an acetaldehyde binding agent can be Proanthocyanidins or Cysteinylglycine, while an upregulator or activator of AMPK and/or SIRT can be Resveratrol, Sulforaphane, Fructose and Curcumin. These ingredients can be sourced from grapes, Broccoli and Curcuma Longa from dietary supplement and plant extract manufacturers around the globe.
As is described hereinabove, the present composition can also include a dietary supplement having anti-gastroparesis, antiemetic, analgesic and/or anti-inflammatory activities.
An example of an antiemetic agent acting as a serotonin (5-HT) antagonist which can be used in the present composition is Proanthocyanidins, Gingerols, Ginsenosides, Bilobalide or Ginkgolides, an anti-Gatroparesis agent acting as TRPV1 agonist and/or TRPA1 agonist can be Eriodictyol, Ursolic Acid, Capsaicin, alpha-
Spinasterol, Gingerols, Shogaols, MSG and Kiwi extract. Eriodictyol is present in a variety of concentrations in extracts of Yerba Santa. Capsaicin is present in a variety of concentrations in extracts of Peppers. Ursolic acid is present in a variety of different concentrations in extracts of Berries and Basil. Gingerols are present in a variety of concentrations in extracts of Ginger. Alpha-Spinasterol is present in a variety of concentrations in extracts of Spinach. MSG is available from a variety of food additive manufacturers.
The present composition can also include a lipid metabolism upregulating agent such as Creatine, Carnitine and Acetyl-L-Carnitine, as well as fish oil.
As is mentioned hereinabove, formulating a product capable of effectively reducing the variety of negative effects of excess alcohol consumption (also referred to herein as an "alcohol recovery product") is challenging due to two main problems: providing a functionally-effective amount of the active ingredients in a consumable product unit to facilitate a rapid and significant physiological effect, and, formulating the product such that the flavor and odor thereof are not unpleasant to the user.
The present inventors have addressed these issues by encapsulating some of the ingredients in microcapsules with different coatings which isolate, rather than mask, the odors and the flavors of unpleasant tasting and smelling active ingredients. Such microcapsules also enable loading of an effective amount of active ingredients in a liquid unit of several hundreds of milliliters, or in a gel. As is further described in the Examples section which follows, microencapsulation was also selected so as to minimize or negate the gritty oral sensation often accompanied with consumption of suspended powders. Such gritty oral sensation of a beverage or a gel is a major obstacle to obtain a satisfactory positive consumption experience by the user.
In addition, the present microencapsulation approaches were designed in order to selectively release different active ingredients (e.g. dietary supplements) throughout the GI tract (see the Examples section which follows for further description).
Several types of micro-encapsulation approaches can be used to encapsulate the dietary supplements of the present composition. Examples of such approaches include encapsulating the dietary supplement raw materials with enteric and/or other encapsulating materials in a fluidized bed; spray-drying a mixture of a dietary supplement and enteric/encapsulant ingredients; and/or; freeze-drying a mixture spray-
drying a mixture of a dietary supplement and enteric/encapsulant ingredients, and then grinding it to the desired final particle size/diameter.
The Examples section which follows describes several approaches for encapsulating the dietary supplements of the present composition. The advantages of the technological approach is that given optimal parameters, it enables the generation of an effective isolative coating even in cases of very small particles of dietary supplements which are characterized by a foul taste and/or odor.
Dietary supplements which are preferably encapsulated include, but are not limited to, Alpha Lipoic Acid, Folic acid, Vitamin B l, Vitamin B2, Vitamin B3 (Nicotinamide), Vitamin B5/Pantethine, Vitamin B6, Vitamin B9 (Folate), Vitamin B 12, Vitamin D, Vitamin E, Glutathione, Carnitine/ Acetyl-L-Carnitine, Cysteine/N- Acetyl-Cysteine, Copper salt, Selenium salt, Magnesium salt, Zinc salt, Pyruvate salt, Co-enzyme A, Curcumin, Piperin, Quercetin, Resveratrol, Sesamin, Sulforaphane, Astaxanthin, Lemon (Limonene), Grape seed (Proanthocyanidins), Huperzia (Huperzine), Pueraria Lobata (Puerarin), Ginseng (Ginsenosides), Ginkgo Biloba (Bilobalide, Amentoflavone, Ginkgolides), Guarana (Caffeine, Theophylline), Ginger (Gingerols, Shogalos), Feverfew (Parthenolides), White Willow Bark (Salicylic acid), Mango (Mangiferin), Betaine (TMG), SAMe, Choline salt, Creatine, Fructose and Glucose.
Tables 1-14 below provide several exemplary compositions formulated according to the teachings of the present invention.
Table 1
Sulphoraphane 35 70
Curcumin 600 1,800
Piperin 60 90
Fructose 20,000 40,000
Betaine (TMG) 3,000 5,000
Choline Bitratrate 1,000 2,000
Creatine 1,000 2,000
American Ginseng (Ginsenosides) 300 900
Ginkgo Biloba (Bilobalide, Ginkgolide B) 300 600
Hovenia Dulcis (Dihydromyricetin) 250 1,000
Pueraria Lobata (Puerarin) 600 3,000
Guarana extract 600 1,200
Glucose 10,000 20,000
Astaxanthin 20 60
Eriodictyol 150 250
Ginger extract (Gingerols, Shogaols) 600 2,000
Feverfew (Parathenolides) 100 200
White Willow Bark (Salicylic acid) 120 240
Table 2
Table 4
Feverfew (Parathenolides) 100 200
White Willow Bark (Salicylic acid) 120 240
Table 8
ango extract ang er n
Table 9
Vitamin D 400IU 400IU
Vitamin E 400IU 400IU
Calcium Pyruvate 2,000 10,000
Betaine (TMG) 3,000 5,000
Choline Bitratrate 1,000 2,000
Co-Enzyme A 500 4,000
Glutathione 500 2,000
Glucose 10,000 20,000
Quercetin 500 1,500
Curcumin 600 1,800
Piperin 60 90
Korean Ginseng (Ginsenosides) 300 900
Ginkgo Biloba (Bilobalide, Ginkgolides) 300 600
Pueraria Lobata (Puerarin) 600 3,000
Ginger extract (Gingerols, Shogaols) 600 2,000
Lemon extract (Limonene) 500 1,500
Huperzia extract (Huperzine) 0.1 0.3
Table 10
ango extract ang er n
Table 11
ango extract ang ern
Table 12
pern
Table 13
Huperzia extract (Huperzine) 0.1 0.3
Table 14
ango extract ang er n
The composition-of-matter of the present invention can be formulated into any consumable product including gels, bars, snacks, shakes or drinks. The composition- of-matter of the present invention is optimized, and thus has significant benefits, when delivered in a water-containing formulation as a suspension or dispersion.
Microencapsulation is a technology that is used to protect ingredients from degradation due to heat, moisture and/or presence of oxygen. Microencapsulation is also used to mask bad odors and tastes of ingredients and to enable controlled and targeted release/delivery of active ingredients in the GI tract.
The present invention utilizes microencapsulation to isolate the taste and organoleptic characteristic (mouth sensation of particles) of various active ingredients and to deliver ingredients to different target sites in the GI tract.
The microencapsulated active ingredients are formulated as a powder which can be dispersed in a liquid beverage, shake or gelprior to consumption.
The powder can be manufactured via spray drying with a three fluid or four fluid injectors incorporating more than a single fluid nozzle and capable of generating, in a single step, a core containing the active ingredient surrounded by at least one layer of a coating made from, for example, cellulose derivatives, proteins, methacrylate and other coating materials known in the food and pharmaceutical industry. Suitable spray drying technologies for use with the present invention include, but not limited to, 3- fluid spray drying, 4-fluid spray drying and ultrasonic dual-fluid or ultrasonic triple- fluid spray drying.
The final microencapsulated product is a powder that is dispersed into, an acidic (2.0 - 4.0) liquid beverage, shake or a gel.
Since the powder is insoluble and includes a high dose of active ingredients, a particle size optimizing dispersion, loading and minimization of a negative mouth sensation (organoleptic) was selected. The present inventors uncovered that a particle diameter for optimizing between particle loading and positive organoleptic sensation ranges between 20-100 microns, with 45 - 75 microns being the preferred size for the aforementioned application.
Suspended particles in liquid with a diameter above 100 microns produce an unpleasant sand-like gritty sensation in the mouth. Human experiments conducted by the present inventors uncovered that particles having a diameter of 15 to 100 microns do not produce such a sensation. In contrast, particles with a diameter of 120 microns or higher, typical to the minimum diameter provided by fluidized bed coating, generate a very unpleasant gritty, sand-like sensation in the mouth.
Thus, an optimal diameter for a microparticle is between 25 - 100 microns and preferably between 45 - 75 microns. A diameter of 45 - 75 microns optimizes between minimum coating loading and a positive oral sensation (and thus an overall positive consumption experience) of a consumer. The ratio of core to coating (w/w) is between 1:10 to 20: 1, preferably in the range between 2:1 to 5: 1.
The microparticles are coated so as to be nearly insoluble in the aqueous environment of the consumed product, and in the mouth and esophagus of the individual consuming it.
As is described in Example 6 below, the powder composition can include several types of particles each offering a different release trigger and a different profile of release of the active ingredient core in the GI tract (stomach and below).
Such selective release can be effected using different types of coating layers that are pH independent, and its disintegration is triggered in presence of enzymes, and augmented mechanical GI tract forces
For example, coatings that are insoluble in non-enzymatic acidic conditions can be fabricated from coating compositions based on Prolamin proteins (Zein, Wheat, etc.), Shellac, fats (Coconut oil, Palm oil, etc.), and any combination thereof. Such coatings can be used to selectively release the active core.
Coatings dissolution in the presence of specific digestive enzymes can be based on Gelatin, Soy proteins, Pea proteins (Globulin), Vegetable proteins, fats, Starches, Dextran, Maltodextrin, Cyclodextrin, Whey and Caseine, and any combination
thereof. Such coatings can be used to release the active core of the micro particle in the stomach.
Coatings dissolution in the presence of a specific digestive enzyme of the small intestines include, but not limited to: Guar gum, gum Arabic, Pectin and Amylose, and any combination thereof. Such coatings can be used to release the active core of the microparticle in the small intestine.
Coatings dissolution in the presence of enzyme of the colon include, but not limited to, Starches, Guar gum, Pectins, Chitosans, Alginates, Hydrogels, and any combination thereof. Such coatings can be used to release the active core of the microparticle in the Colon.
Coatings dissolution under low pH conditions include, but not limited to, Polymethacrylates. Such coatings can be used to release the active core of the microparticle in the stomach.
Other coatings that facilitate slow-release/controlled release, independent of enzymatic and pH conditions include, but not limited to, Ethyl Cellulose. Such coatings can be used for controlled release of an active core throughout the GI tract, water-soluble coatings include, but not limited to, Methyl Cellulose. Such coatings can be used in combination with the coatings described above in order to accelerate dissolution under the aforementioned conditions.
The encapsulating layer of the microparticles can be non-uniform to allow selective dissolution of the microparticles and prolonged selective release of the active ingredient. Several approaches for enabling selective release of active ingredients from coated microparticles are described in the Examples section which follows.
When the encapsulated microparticles are reconstructed into a liquid-based composition, the microparticles are preferably suspended in the liquid and are homogenously distributed therein (e.g. not floating at the surface of the liquid and not settling at the bottom of the container).
The encapsulated microparticles are inert or materially inert in as far as taste and odor, or, incorporate a flavoring agent which masks or at the minimum materially masks the taste of the encapsulating coating layer. Following contact with the liquid, the encapsulation coating layer of the dietary supplement is designed not to dissolve or breakdown (e.g. to release its active core content) in the acidic non-enzymatic conditions of the liquid or the gel for at least 20 minutes. This enables the
microparticles to survive as a suspension in the liquid/gel and pass through the mouth and esophagus without substantially releasing its contents. Once passed the esophagus, the composition begins to release its active ingredients (in a selective and controlled manner) in the stomach and/or the small intestines and/or in the colon, depending on the viscosity of the carrier, the properties of the coating layer and the (w/w) ratio between the encapsulation material and active ingredients.
As is mentioned hereinabove, the present composition can include more than one type of a micro particle in a single powdered product. Different types of microparticles can include different cores (i.e. different active ingredient) and/or a different type of coating (facilitating selective release of more than one active ingredient).
For example, a single powdered dose unit can include:
(a) a microparticle facilitating rapid release of ingredient X (a dietary supplement) in the stomach
(b) a microparticle facilitating delayed release of ingredient Y (a dietary supplement) in the intestines (delay of 15 - 120 minutes post consumption); and
(c) a microparticle facilitating delayed release of ( a dietary supplement) ingredient Z in the colon along (delay of 15 - 480 minutes post consumption). Each micro-particle has a core with at least one active ingredient. The active ingredient of the core can be mononuclear, multi-nuclear or incorporated in a slow- release or controlled release matrix. The core can also incorporate intestinal permeability enhancing agents.
Each microparticle can include more than one coating layer, e.g. two or more coating layers each having a different dis solvability profile.
A single coating layer is intended for use in beverages or other reconstructed compositions having a high-water content. A single layer of coating is designed to prevent the release of foul-tasting ingredients into the water for a time period sufficient for a common consumer to completely consume a 330 - 500 ml serving, e.g. 20-30 minutes.
A single encapsulation layer incorporating at least 2 coating materials each having a different dis solvability profiles can be used to obtain stepwise release profiles.
The microencapsulated active ingredients of the present invention can also be provided in a Ready-To-Drink (RTD) beverage. In order to provide a reasonable shelf-life for the RTD version, more than a single encapsulation coating layer is required. A first (and inner) encapsulation coating layer can control release as described above and at least one additional encapsulation layer can be used to seal the core and 1st encapsulation layer from the water in the RTD product. Such an outer encapsulation coating layer is designed for maximum sealing, and is rapidly breached under the enzymatic and/or mechanical grinding conditions of the stomach thereby exposing the inner encapsulation layer and its selective dissolution thereof.
The outer (second) encapsulation coating layer can include materials which are insoluble in acidic, non-enzymatic conditions, but are rapidly dissolved/disintegrated under the enzymatic and/or mechanical grinding conditions of the stomach. Such materials include, but not limited to, Prolamin proteins (Zein, Wheat, etc.) and fats (Coconut oil, Palm oil) and any combinations thereof.
Table 15 below describes release profiles of several types of products.
Table 15 - release profiles of various powders
Release In Release In Release In Release In Controlled Controlled Beverage / Mouth Esophagus Stomach Release In Release In Gel Media Small Colon
Intestines
0% - 5% 0% - 2% 0% - 2% 1% - 33% 66% - 95% 1% - 33%
Alcohol Glutathione Glutathione Glutathione Glutathione Glutathione Glutathione
Metabolism ALA ALA ALA ALA ALA ALA
Vitamin Bl Vitamin Bl Vitamin Bl Vitamin Bl Vitamin Bl Vitamin Bl
Acceleration Vitamin B2 Vitamin B2 Vitamin B2 Vitamin B2 Vitamin B2 Vitamin B2
Vitamin B3 Vitamin B3 Vitamin B3 Vitamin B3 Vitamin B3 Vitamin B3
Vitamin B5 Vitamin B5 Vitamin B5 Vitamin B5 Vitamin B5 Vitamin B5
Vitamin B6 Vitamin B6 Vitamin B6 Vitamin B6 Vitamin B6 Vitamin B6
Vitamin B9 Vitamin B9 Vitamin B9 Vitamin B9 Vitamin B9 Vitamin B9
Vitamin B12 Vitamin B12 Vitamin B12 Vitamin B12 Vitamin B12 Vitamin B12
Vitamin D Vitamin D Vitamin D Vitamin D Vitamin D Vitamin D
Vitamin E Vitamin E Vitamin E Vitamin E Vitamin E Vitamin E
Coenzyme A Coenzyme A Coenzyme A Coenzyme A Coenzyme A Coenzyme A
Acetyl- L- Acetyl- L- Acetyl- L- Acetyl-L- Acetyl- L- Acetyl- L-
Carnitine Carnitine Carnitine Carnitine Carnitine Carnitine
NAC NAC NAC NAC NAC NAC
Magnesium Magnesium Magnesium Magnesium Magnesium Magnesium
Zinc Zinc Zinc Zinc Zinc Zinc
Quercetin Quercetin Quercetin Quercetin Quercetin Quercetin
Resveratrol Resveratrol Resveratrol Resveratrol Resveratrol Resveratrol
Sulforaphane Sulforaphane Sulforaphane Sulforaphane Sulforaphane Sulforaphane
Betaine /TMG Betaine /TMG Betaine /TMG Betaine / TMG Betaine /TMG Betaine /TMG
Choline Choline Choline Choline Choline Choline
Glucose Glucose Glucose Glucose Glucose Glucose
Cognitive & 0% - 5% 0% - 2% 0% - 2% 1% - 33% 66% - 95% 1% - 33% motor Ginkgo extract Ginkgo extract Ginkgo extract Ginkgo extract Ginkgo extract Ginkgo extract
(Bilobalide, (Bilobalide, (Bilobalide, (Bilobalide, (Bilobalide, (Bilobalide,
Performance Gikgolides) Gikgolides) Gikgolides) Gikgolides) Gikgolides) Gikgolides)
Recovery Kudzu extract Kudzu extract Kudzu extract Kudzu extract Kudzu extract Kudzu extract
(Puerarin) (Puerarin) (Puerarin) (Puerarin) (Puerarin) (Puerarin)
Lemon extract Lemon extract Lemon extract Lemon extract Lemon extract Lemon extract
(Limonene) (Limonene) (Limonene) (Limonene) (Limonene) (Limonene)
Huperzia Huperzia Huperzia Huperzia Huperzia Huperzia extract extract extract extract extract extract
(Huperzine) (Huperzine) (Huperzine) (Huperzine) (Huperzine) (Huperzine)
Ginseng extract Ginseng Ginseng Ginseng Ginseng Ginseng
(Ginsenosides) extract extract extract extract extract
Curcumin (Ginsenosides) (Ginsenosides) (Ginsenosides) (Ginsenosides) (Ginsenosides)
Curcumin Curcumin Curcumin Curcumin Curcumin
0% - 5% 0% - 2% 0% - 2% 1% - 20% 20% - 80% 20% - 80%
Nausea, pain Grape seed Grape seed Grape seed Grape seed White Willow White Willow
& extract extract extract extract Bark extract Bark extract
(Proantho (Proantho (Proantho (Proantho (Salicin) (Salicin) physiological cyanidins) cyanidins) cyanidins) cyanidins) Grape seed Grape seed discomfort Feverfew Feverfew Feverfew Feverfew extract extract reduction (Parthenolides) (Parthenolides) (Parthenolides) (Parthenolides) (Proantho (Proantho
Ginger Ginger Ginger Ginger cyanidins) cyanidins)
(Gingerols & (Gingerols & (Gingerols & (Gingerols & Feverfew Feverfew
Shogaols) Shogaols) Shogaols) Shogaols) (Parthenolides) (Parthenolides)
Ginger Ginger (Gingerols & (Gingerols & Shogaols) Shogaols)
0% - 5% 0% - 2% 0% - 2% 33% - 66% 33% - 66% 0% - 2%
Gastric Mango extract Mango extract Mango extract Mango extract Mango extract Mango extract motility (Mangiferin) (Mangiferin) (Mangiferin) (Mangiferin) (Mangiferin) (Mangiferin)
Piperin Piperin Piperin Piperin Piperin Piperin recovery
The composition-of-matter of the present invention can be formulated as a ready-to-consume water-based drink, shake or gel which includes any of the above described ingredients as well as colorants, thickeners, flavoring agents, stabilizers and the like, or, as a powder containing the microencapsulated microparticles to be reconstituted in a drink or a gel prior to its consumption.
A composition-of-matter formulated as a drink is also served in a container which maintains at least some of the active ingredients in powder form and isolated from the liquid carrier.
Thus, according to another aspect of the present invention, there is provided an article of manufacturing which includes a container having two environmentally isolated compartments, one compartment for containing active ingredients in powder form, and the other for containing water and optionally dissolved components such as Fructose, Glucose, Betaine, Choline salt, and Creatine.
Figure 1 illustrates one such container which is referred to herein as container 10. Container 10 is preferably shaped as elongated cylinder 25 cm in height, 6.5 cm in diameter and having a volume of 300-700 ml. Container 10 can be fabricated from, but not limited to, PET or Polypropylene using well known approaches. Container 10 includes two, environmentally-isolated, compartments (12 and 14) which are separated by partition 16. Container 10 further includes an opening 18 for accessing the contents of container 10, opening 18 can be sealed via a single use cover such as a pull tab, or a multi-use cover such as a screw cap. First compartment 12 is designed for containing the composition-of-matter described herein (e.g. the active ingredients of Table 2), while second compartment 14 is designed for containing the liquid carrier (water, optionally with dissolved components). Container 10 is designed such that partition 16 is breachable prior to unsealing of opening 18 thus enabling a user to mix the components of compartment 12 with the liquid of compartment 14 prior to consumption.
Partition 16 can be breached via one of several mechanisms which can be functionally connected to a lid or cap covering opening 18. For example, a screw cap covering opening 18 can be physically connected to partition 16 such that unscrewing of the screw cap breaches partition 18.
In any case, once wall 16 is breached by the user, the container can be vigorously shaken in order to dissolve and/or suspend the active ingredients in the water prior to consumption.
Thus, the present invention provides a composition-of-matter which can be used to counteract the negative effects of alcohol consumption in a rapid and timely manner.
The composition of the present invention concurrently and timely addresses three key aspects of excess alcohol consumption by providing effective alcohol catabolism, improvements in motor, cognitive, attention, task switching, quality decision making and reduced risk taking behavior; and improvements in physiological sensations/feeling. Since the present composition can include relatively large quantities of water it also provides a beneficial rehydration effect along with large quantities of active ingredients.
The present composition was designed for consumption following (e.g. after) alcohol uptake so as to not influence the desired positive effects of alcohol consumption from the consumer's subjective perception. However, consumption of the present composition prior to and/or concurrently with, alcohol consumption, would prevent blood alcohol levels from peaking and thus would prevent or at least reduce motor and cognitive performance from degrading.
As used herein the term "about" refers to ± 10 %.
Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting.
EXAMPLES
Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.
EXAMPLE 1
Encapsulation of Glucose
Glucose with a pre-encapsulation diameter of 25 microns was encapsulated with a shellac -based composition. The shellac encapsulate included 65 grams of Shellac (SSB 57), 15 grams of Glycerin, 20 grams of HPMC (Vivapur E5LV), 3 grams of talcum and 600 grams of water.
A fluidized bed was used for encapsulating the Glucose under the following conditions: Pressure blow back: 1.3 - 2.1 [bar]; Pressure pump feed: 3.4 [bar]; Spraying pressure: 2.5 [bar]; Airflow: 3.0 [M3 per second]; Air temperature: 40 [Celsius].
150 grams of Glucose and 75 grams of the Shellac -based composition (50% encapsulation) were processed via 7 cycles of the following: 108 seconds of mixing with the encapsulation composition + 600 seconds of drying the encapsulated Glucose without additional free encapsulate.
Figure 2 illustrates the non-encapsulated Glucose (left image) and Shellac- based encapsulated Glucose (right image).
Encapsulated Glucose was placed under conditions simulating the stomach (pH 1.2) for 30 minutes, and then under conditions simulating the small intestines (pH 6.8). A D-Glucose UV Test (R-Biopharm) was used to analyze the quantity of Glucose released to the surrounding media. Following 30 minutes at pH 1.2 (stomach), 10% of the Glucose was released to the surrounding media. At pH 6.8 (intestines), all the remaining Glucose was released to the surrounding media following 40 minutes.
EXAMPLE 2
Accelerating alcohol catabolism in human subjects A study on 19 participants (9 males and 10 females, ages 21 - 29), evaluated the increase in alcohol catabolism between control (no dietary supplements) and study arm (with the composition of matter) after each of the participants consumed 500cc of beer with 4.9% alcohol (e.g. 24.5 cc of pure alcohol). Table 16 below summarizes the findings.
Table 16
# Gender Blood Control Composition Diff BAC%/h
Volume 30m - End 30m - End 30m - End
BAC%/h BAC%/h (%)
1 M 6, 160 0.015% 0.027% 79%
2 M 5,313 0.012% 0.021 % 80%
3 F 3,243 0.017% 0.018% 7%
4 F 4,221 0.009% 0.016% 81 %
5 M 5,498 0.011 % 0.015% 31 %
6 M 6,391 0.011 % 0.016% 46%
7 F 4, 134 0.009% 0.015% 62%
8 F 3,685 0.019% 0.022% 18%
9 F 4,020 0.018% 0.029% 63%
10 M 4,620 0.014% 0.018% 35%
11 M 5,082 0.011 % 0.019% 66%
12 F 4,221 0.018% 0.022% 25%
13 F 3,450 0.013% 0.019% 47%
14 M 4,620 0.010% 0.015% 48%
15 M 5,621 0.011 % 0.023% 101 %
16 F 5,226 0.013% 0.022% 71 %
17 F 3,685 0.017% 0.017% 0%
18 F 3,685 0.012% 0.014% 22%
19 M 4,312 0.015% 0.019% 31 %
20
General
Average 0.013% 0.019% 48%
Median 0.013% 0.019% 47%
SD 0.003% 0.004% 28%
P-value 0.00000
Males
Average 0.012% 0.019% 57%
Median 0.011 % 0.019% 48%
SD 0.002% 0.004% 25%
Females
Average 0.015% 0.019% 40%
Median 0.015% 0.019% 36%
SD 0.004% 0.004% 29%
The median alcohol catabolism rate was 0.019%/h in the composition-treated individuals vs. 0.013%/h in the control army, a 47% advantage (p=0.00000). In men,
the median alcohol catabolism rate was 0.019%/h in the composition-treated individuals vs. 0.011%/h in the control arm, a 48% advantage. In women, the median alcohol catabolism rate in the composition study was 0.019%/h in the composition- treated individuals vs. 0.015%/h in the control arm, a 36% advantage.
EXAMPLE 3
Increasing motor and cognitive performance in human subjects
A 53 years old male, who does not frequently consume alcohol and weighs 85 kg, fasted for 2 hours prior to consuming 59 grams of alcohol (71 cc of 96% alcohol) admixed with 160cc of Cold Forrest berries' juice. It took the individual 20 minutes to consume the liquid. Twenty minutes following consumption, the participant consumed a composition of matter which included dietary supplements selected for improving motor and cognitive functions.
The cognitive and motor functions of the individual were evaluated using a 'lost in migration' test (Figure 3), 'decision making' test (Figure 4), 'spatial' test (Figure 5) and 'speed' test (Figure 6) using standard techniques. As is shown by the table data and graphs of these Figures, the present composition significantly reduced the time it took the individual to return to normal function, when compared to a control without the composition. In addition, the decline in performance after consuming the composition was lower when compared to the control.
EXAMPLE 4
Improving motor, cognitive and impulse control in a group of participants under the influence of high blood alcohol
A study on 24 participants (12 males and 12 females, ages 21 - 29), evaluated motor, cognitive and impulse control between placebo (dietary supplements with no effect on motor, cognitive and impulse control performance) and the present composition of matter. The placebo and composition sessions were scheduled at least 7 days apart to avoid interference between the sessions.
For the purpose of the study, the following motor and cognitive studies from the Lumosity web site were used:
• Speed Match Overdrive (testing information processing and memory)
• Color Match (testing response inhibition)
• Birds in Migration (testing selective attention)
• Ebb and Flow (testing task switching)
Each participant trained on each test for at least 3 hours to reach the highest level of self-proficiency and performance in order to avoid a learning curve during the study itself.
Prior to the consumption of alcohol, participants performed each test 5 times, to record the baseline performance for the specific day of testing. The 5 results were averaged to obtain a calculated score for each test.
After each participant consumed an alcohol quantity calculated to bring his/her blood alcohol level to 0.1%, every 15 minutes, a blood alcohol level was measured for each participant (using the BACtrack S75 breathalyzer) which then performed the battery of cognitive tests from the Lumosity web site. At 45 minutes following the end of alcohol consumption, each participant consumed either the placebo composition or the present composition. (Participants were told the Placebo composition was an effective composition). Each session ended 3.5 hours following the completion of alcohol consumption.
All 4 tests demonstrated advantage of the study composition arm over the placebo arm. As the 4 tests evaluated information processing + memory; inhibition, selective attention; and; task switching, it can thus be concluded that the present composition is effective in improving motor and cognitive performance in individuals under the influence of high blood alcohol (above 0.08%).
Tables 17 and 18 below present response time and normalized result (response time divided by accuracy %, generating a value representing response time in milliseconds at 100% accuracy) of placebo and present composition. The comparison time points, 15 minutes and 45 minutes, were measured from the time the participant started consuming the dietary supplements:
Table 17
Comparison between placebo and the present composition - reaction time (ms)
15 minutes after 45 minutes after
supplements supplements
consumption consumption
Placebo Composition Diff. Placebo Composition Diff.
Speed Match
664 645
Overdrive 19 650 630 20
Color Match 667 653 14 663 639 24
Birds in Migration 665 645 20 660 640 20
Ebb & Flow 580 568 12 575 562 13
The Diff. represents the advantage (or disadvantage) of the response time in the Composition study vs. the Placebo study. (All values in the table are in Milliseconds). As can be viewed from the table above, there is a consistent advantage in response time in the Composition study vs. the Placebo study.
Table 18
Comparison between placebo and the present composition - normalized results
The Diff. value represents the advantage (or disadvantage) of the response time in the Composition study vs. the Placebo study. (All values in the table are in Milliseconds representing response time @ theoretical 100% response accuracy). As can be viewed from the table above, except in a single measurement, there is a consistent advantage in response time in the Composition study vs. the Placebo study.
EXAMPLE 5
Acidic water resistant micro-encapsulation of Vitamin B2 (core) in Zein
An experiment was conducted in order to test the release profile of encapsulated vitamin B2 in an enzyme-free, acidic environment simulating the conditions of a beverage (after reconstruction of the powdered composition).
Vitamin B2 was encapsulated with a prolamine-based coating. Prolamine proteins are water-insoluble, and edible (food-grade).
A mini (lab-scale) spray dryer Buchi B-290 equipped with an advanced inert loop under nitrogen was used to encapsulate the Vitamin B2 with a 3 -fluid Buchi nozzle under the following conditions:
20g of Vitamin B2 were dispersed in 80g of ethanol (or water)
15g of Zein protein was dissolved in an 80g ethanol + 20% water solution
Parameters of spraying:
Inlet temp: 1100C
Outlet temp: 750C
Aspirator: 100%/35m3/h
Feed rate core/shell: 5ml/min /lOml/min
Spray gas flow: 50mm
Particle size: d90 ~ 20 microns
The final product was collected and placed under condition simulating the enzyme-free acidic condition of the reconstructed beverage (only acid 1.1%).
The Vitamin B2 was tested in a spectrophotometer Perkin ELMER LAMBADA 25 at wavelength 268nanometer that is typical for Vitamin B2 absorbance.
At the first 10 minute time mark, no release of Vitamin B2 was observed. After 20 min, ~7 % was released to the surrounded media. After 30 min, -15% was released. After 60 and 120 minutes no further release was observed (Figure 7).
EXAMPLE 6
Powders having more than one microparticle type
Composition-of-matter 1
This composition-of-matter includes the two microparticle types shown in Figures 8a-b.
The microparticle in Figure 8a has a core (A) with a diameter of 50 microns, and a coating layer (B) 5 microns thick, bringing the final diameter of the particle to 60 microns. The particle of Figure 8a includes a Ginger-extract active core surrounded by a zein-based coating layer. The coating layer of this particle is designed to be materially insoluble in non-enzymatic acidic conditions of the beverage, and to rapidly dissolve in the enzymatic conditions of the stomach.
The particle of Figure 8b has a core (C) with a diameter of 55 microns, and a coating layer (D) 5 microns thick, bringing the final diameter of the particle to 65 microns. The particle is Figure 8b includes a Ginger extract active core surrounded by a coating layer of Shellac + HPMC. The coating layer of this particle is designed to be materially insoluble in the non-enzymatic acidic conditions of the beverage, materially insoluble in the acidic enzymatic conditions of the stomach, and to gradually dissolve in the enzymatic and pH conditions of the small intestines.
A composition-of-matter including these two microparticle types enables rapid release of the Ginger extract (from the particle in Figure 8a) in the stomach thereby positively affecting local recovery of gastric motility through Ginger's 5-HT3 antagonistic properties, and to facilitate rapid absorption of Ginger constituents starting in the Duodenum for affecting brain receptor in the alleviation of nausea and vomiting. The later release of the Ginger extract (from the particle in Figure 8b) in the small intestines starting from the Jejunum facilitates the continuation of Ginger constituents absorption and maintenance of its anti-emetic brain properties,
Composition-of-matter 2
This composition-of-matter includes the three microparticle types shown in Figures 9a-c.
The microparticle of Figure 9a has a core (E) with a diameter of 50 microns, and a coating layer (F) 10 microns thick, bringing the final diameter of the particle to 70 microns. The particle in Figure 9a includes Ginger extract and Piperin in the active core surrounded by a coating layer which includes Zein and a Cellulose derivative. The coating layer of this particle is designed to be materially insoluble in non- enzymatic acidic conditions of the beverage, and to rapidly dissolve in the enzymatic conditions of the stomach.
The microparticle of Figure 9b has a core (G) with a diameter of 60 microns, and a coating layer (H) 7.5 microns thick, bringing the final diameter of the particle to 75 microns. The particle is Figure 9b includes Ginger extract and Piperin as the active core, surrounded by a coating layer which includes Zein and Shellac. The coating layer of this particle is designed to be materially insoluble in the non-enzymatic acidic conditions of a beverage, materially insoluble in the acidic enzymatic conditions of the
stomach, and gradually dissolve in the enzymatic and pH conditions of the small intestines.
The microparticle of Figure 9c has a core (I) with a diameter of 45 microns, and a coating layer (J) 7.5 microns thick, bringing the final diameter of the particle to 60 microns. The particle of Figure 9c includes a Ginger extract active core surrounded by a coating layer which includes cross-linked Alginate. The coating layer of this particle is designed to be materially insoluble in the non-enzymatic acidic conditions of the beverage, materially insoluble in the acidic enzymatic conditions of the stomach, materially insoluble in the enzymatic and pH conditions of the small intestines, and, gradually dissolve in the enzymatic and pH conditions of the Colon.
A composition-of-matter including these three microparticle types enables rapid release of the Ginger extract and the Piperin (from the particle in Figure 9a) in the stomach positively affects local recovery of gastric motility through Ginger's 5- HT3 antagonistic properties and Piperin' s TRPV1 agonistic properties, and to facilitate rapid absorption of Ginger constituents starting in the Duodenum for affecting brain receptor in the alleviation of nausea and vomiting; and; to facilitate Piperin' s intestinal absorption enhancement properties. The later release of the Ginger extract and Piperin (from the particle in Figure 9b) in the small intestines starting from the Jejunum facilitates the continuation of Ginger constituents absorption and maintenance of its anti-emetic brain properties; and; Piperin' s continued enhancement of intestinal absorption, The targeted Colonic release of the Ginger extract (from the particle of Figure 9c) further facilitates its continued availability in the brain and anti-emetic action. In summary, this composition combines rapid recovery of gastric motility, enhancement of intestinal absorption and facilitation and maintenance of up to 8 hours of alleviating nausea and/or or vomiting sensations.
Composition-of-matter 3
This composition-of-matter includes the three microparticle types shown in Figures lOa-c.
The microparticle of Figure 10a has a core (K) with a diameter of 55 microns, and a coating layer (L) 5 microns thick, bringing the final diameter of the particle to 65 microns. The microparticle in Figure 10a includes a Mangiferin active core surrounded by a coating layer which includes fat and Cellulose. The coating layer of this particle
is designed to be materially insoluble in non-enzymatic acidic conditions of the beverage, and to to rapidly dissolve in the enzymatic conditions of the stomach.
The particle of Figure 10b has a core (M) with a diameter of 50 microns, and a coating layer (N) 5 microns thick, bringing the final diameter of the particle to 60 microns. The particle of Figure 10b includes Mangiferin and White Willow Bark extract (Salicin) as the active core surrounded by a coating layer including Ethyl Cellulose, MCG (Medium Chain Glycerides) and Oleic Acid. The coating layer of this particle is designed to be materially insoluble in the non-enzymatic acidic conditions of the beverage, materially insoluble in the acidic enzymatic conditions of the stomach, and to gradually dissolve in the enzymatic and pH conditions of the small intestines.
The particle of Figure 10c has a core (O) with a diameter of 45 microns, and a coating layer (P) 5 microns thick, bringing the final diameter of the particle to 55 microns. The particle of Figure 10c includes White Willow Bark extract (Salicin) as the active core, surrounded by a coating layer including Alginate and Starch. The coating layer of this particle is designed to be materially insoluble in the non- enzymatic acidic conditions of the beverage, materially insoluble in the acidic enzymatic conditions of the stomach, materially insoluble in the enzymatic and pH conditions of the small intestines, and, gradually dissolve in the enzymatic and pH conditions of the Colon.
A composition-of-matter including these three microparticle types enables rapid release of Mangiferin (from the microparticle in Figure 10c) in the stomach positively affecting local recovery of gastric motility of the stomach through Mangiferin's 5-HT4 agonistic properties and facilitating rapid activation of intestinal 5-HT4 receptors by Mangiferin starting in the Duodenum. The later release of the Mangiferin and Salicin (from the microparticle in Figure 10b) in the small intestines starting from the Jejunum facilitates the continuation of Mangiferin's impact on the recovery of intestinal motility and Salicin' s intestinal absorption and antagonistic action on the brain's 5-HT2 receptors, alleviating pain and headache, The targeted Colonic release of the Salicin (from the microparticle of Figure 10c) further facilitates its continued availability in the brain and anti-headache / migraine action. In summary, this composition, with its 3 coating implementations, combines rapid recovery of
gastric motility, and facilitation and maintenance of up to 8 hours of alleviating pain, headache and/or or migraine sensations.
Composition-of-matter 4
This composition-of-matter was designed for a shelf life of over 3 months after reconstruction into an orally-deliverable gel. This composition is manufactured using a spray dryer with a 4-fluid injector, where 3 of the 4 channels are fed with fluids and/or melted fat, and single channel is utilizing air or Nitrogen, as applicable.
This composition-of-matter includes the three microparticle types shown in Figures l la-c.
The microparticle of Figure 11a has a core (Q) with a diameter of 40 microns, a first and inner coating layer (R) 10 microns thick, bringing the diameter of the particle to 60 microns and a second and outer coating layer (S) 5 microns thick, bringing the final diameter of the particle to 70 microns.
The microparticle of Figure 11a includes Ginger extract and Piperin as the active core surrounded by an inner coating layer including Zein and a Cellulose derivative, and an outer coating layer including Gelatin and fat (Carnauba, Stearic acid, Sunflower). The outer coating layer improves the impermeability of the particle to acidic water and/or dissolution in acidic water-containing gel (thus providing longer shelf-life), but is quickly dissolvable in the enzymatic conditions of the stomach. The inner coating layer of this particle is designed to be materially insoluble in non- enzymatic acidic conditions of the gel, and to rapidly dissolve in the enzymatic conditions of the stomach.
The microparticle of Figure 1 lb has a core (T) with a diameter of 50 microns, a first and inner coating layer (U) 10 microns thick, bringing the diameter of the particle to 60 microns and a second and outer coating layer (V) 5 microns thick, bringing the final diameter of the particle to 70 microns.
The microparticle of Figure l ib includes Ginger extract and Piperin as the active core surrounded by an inner coating layer including Zein and Shellac, and an outer coating layer including Gelatin and fat (Carnauba, Stearic acid, Sunflower). The outer coating layer improves the impermeability of the particle to acidic water and/or dissolution in acidic water-containing gel (thus providing longer shelf-life), but is quickly dissolvable in the enzymatic conditions of the stomach. The inner coating
layer of this particle is designed to be materially insoluble in the non-enzymatic acidic conditions of the gel, materially insoluble in the acidic enzymatic conditions of the stomach, and to gradually dissolve in the enzymatic and pH conditions of the small intestines.
The microparticle of Figure 11c has a core (W) with a diameter of 45 microns, a first and inner coating layer (X) 5 microns thick, bringing the diameter of the particle to 55 microns and a second and outer coating layer (Y) 5 microns thick, bringing the final diameter of the particle to 65 microns.
The microparticle of Figure 11c includes a Ginger extract active core surrounded by an inner coating layer of cross-linked Alginate and an outer coating layer of Gelatin and fat (Carnauba, Stearic acid, Sunflower). The outer coating layer improves the impermeability of the particle to acidic water and/or dissolution in acidic water-containing gel (thus providing longer shelf -life), but is quickly dissolvable in the enzymatic conditions of the stomach. The inner coating layer of this particle is designed to be materially insoluble in the non-enzymatic acidic conditions of the gel, materially insoluble in the acidic enzymatic conditions of the stomach, materially insoluble in the enzymatic and pH conditions of the small intestines, and gradually dissolve in the enzymatic and pH conditions of the Colon.
A composition-of-matter including these three microparticle types enables rapid release of the Ginger extract and the Piperin (from the microparticle of Figure 11a) in the stomach positively affects local recovery of gastric motility through Ginger's 5-HT3 antagonistic properties and Piperin's TRPV1 agonistic properties, and facilitating rapid absorption of Ginger constituents starting in the Duodenum for affecting brain receptor in the alleviation of nausea and vomiting and facilitating Piperin's intestinal absorption enhancement properties. The later release of the Ginger extract and Piperin (from the microparticle in Figure l ib) in the small intestines starting from the Jejunum facilitates the continuation of Ginger constituents absorption and maintenance of its anti-emetic brain properties and Piperin's continued enhancement of intestinal absorption. The targeted Colonic release of the Ginger extract(from the microparticle of Figure 11c) further facilitates its continued availability in the brain and anti-emetic action. In summary, this composition, with its 3 coating implementations, combines rapid recovery of gastric motility, enhancement
of intestinal absorption and facilitation and maintenance of up to 8 hours of alleviating nausea and/or or vomiting sensations.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub -combination.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.
Claims
1. A composition-of-matter comprising at least two types of microparticles each formed from an active ingredient core encapsulated by at least one coating layer incorporating at least one coating material, said at least two types of said microparticles being differentiated by said active ingredient or said at least one coating material.
2. The composition-of-matter of claim 1, wherein each of said at least two types of said microparticles is capable of releasing said active ingredient at a different region of a GI tract.
3. The composition-of-matter of claim 1, wherein said microparticles have a diameter of 25-100 microns.
4. The composition-of-matter of claim 1, wherein said microparticles include one or more active ingredients selected from the group consisting of:
(a) dietary supplements affecting motor and cognitive performance;
(b) dietary supplements having anti-gastroparesis, antiemetic, analgesic and anti-inflammatory activities; and/or
(c) dietary supplements capable of increasing alcohol catabolism.
5. The composition-of-matter of claim 4, wherein said microparticles comprise (a) and (b), (b) and (c) or (a) and (c).
6. A beverage, shake or gel comprising a dispersion of the composition- of-matter of claim 1 in an aqueous medium.
7. The beverage of claim 6, wherein a pH of said beverage is 2.4-3.5.
8. The composition-of-matter of claim 4, wherein said dietary supplement affecting motor and cognitive performance is selected from a group consisting of Bilobalide, Ginkgolides (A, B & C), Puerarin, Resveratrol, Quercetin, Curcumin, Caffeine, Theophylline, Amentoflavone, Dihydromyricetin, Copper Glycinate Chelate, Huperzine A, Rosmarinic acid, Parthenolides, Salicin, Eriodictyol, Alpha Lipoic Acid, 1-Cysteine, N-Acetyl-Cysteine, Magnesium, Zinc, Amentoflavone, Adiantum venestum, Amaranthus virdis, Houttuynia cordata, Minthostachys mollis, Sargassum fusiforme, Usnea florida, Limonene, Proanthocyanidins, Zinc, Sulforaphane, Menthol, Gingerols, Shogaols and Parthenolides.
9. The composition-of-matter of claim 4, wherein said dietary supplement affecting motor and cognitive performance is selected from a group consisting of Bilobalide, Huperzine A, N-Acetyl-Cysteine, L-Carnitine, Acetyl-L-Carnitine, Glutamic acid, Glycine, L-Glutamate, L-Aspartate, L-Alanine, Magnesium salt, Zinc salt, Polygala Limonene, Tenuifolia, Acorus gramineus, Poria cocos, Limonene, Gingerols, Shogaols, Sulforaphane, Betaine, L-Cysteine and Mangiferin.
10. The composition-of-matter of claim 4, wherein said dietary supplement having anti-gastroparesis, antiemetic, analgesic and anti-inflammatory activities is selected from a group consisting of Curcumin, Thunder God Vine, Resveratrol, Quercetin, Kaempferol, Pycogenol, Parthenolides, EGCG, Ursolic acid, Berberine, Ginsenosides, gingerols, shogaols, Salicin and Hesperidin, Vitamin C, Mangosteen, and Butterbur.
11. The composition-of-matter of claim 4, wherein said dietary supplement having anti-gastroparesis, antiemetic, analgesic and anti-inflammatory activities is selected from a group consisting of Shogaols, Piperin, Magnesium salt, Zinc salt, Omega-3, Achinacea, Carvone, Camphor, Mustard oil and Carnosol.
12. The composition-of-matter of claim 4, wherein said dietary supplement capable of increasing alcohol catabolism is selected from a group consisting of B Vitamins: 1,2,3,5,6,9 and 12, Pantethine, Vitamin D, Vitamin E, TMG (Betaine), Choline salt, Zinc salt, SAMe, Nicotinamide, Folate / Folic acid, Alpha Lipoic Acid,
Co-enzyme A, Proanthocyanidines, Cysteinylglycine, Magnesium salt, Sulforaphane, L-Cysteine, N-Acetyl-Cysteine, Resveratrol, Quercetin, Caffeine, Theophylline, L- Carnitine, Acetyl-L-Carnitine, Pyruvate salt, Fructose, Bilobalide, Puerarin, Shogaols, Salicin, Sulforaphane, Menthol, Curcumin and Sulforaphane.
13. The composition-of-matter of claim 4, wherein said dietary supplement capable of increasing alcohol catabolism is selected from a group consisting of Quercetin, Caffeine, Theophylline, Curcumin, Sulforaphane, Eriodictyol, Betaine / TMG, L-Cysteine, N-Acetyl-Cysteine and Pyruvate salt.
14. An article of manufacturing comprising a container having two environmentally isolated compartments, a first compartment including the composition-of-matter of claim 1 and a second compartment including a liquid.
15. The article of manufacturing of claim 14, wherein said container is constructed so as to enable mixing of said composition-of-matter with said liquid to generate a consumable suspension.
16. The article of manufacturing of claim 14, wherein the composition-of- matter includes at least one active ingredient selected from the group consisting of Bilobalide, Ginkgolides, Amentoflavone, Dihydromyricetin, Puerarin, Limonene, Huperzine, Quercetin, White Willow Bark, Feverfew, Grape Seed Extract, Alpha Lipoic Acid and Co-Enzyme A, .
17. The composition-of-matter of claim 1, wherein said at least one coating material is selected from the group consisting of HPMC, HPMPC, Carbomers, PEGs, Prolamin proteins (Zein, Wheat, etc.), Shellacs, fats (Coconut oil, Palm oil, Carnauba wax, Stearic acid, Sunflower oil), Gelatin, Soy proteins, Pea proteins (Globulin), Vegetable proteins, Starches, Dextran, Maltodextrin, Cyclodextrin, Whey, Caseine, Guar gum, gum Arabic, Pectin, Amylose, Pectins, Chitosans, Alginates, Hydrogels, HMPC, HPMPC, PVA, PEGs, Carbomers, Polymethacrylate, Ethyl Cellulose and Methyl Cellulose.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES15845037T ES2919874T3 (en) | 2014-09-24 | 2015-09-20 | Compositions and methods for selective delivery to the gastrointestinal tract |
EP15845037.9A EP3197436B1 (en) | 2014-09-24 | 2015-09-20 | Compositions and methods for selective gi tract delivery |
US15/513,672 US11229600B2 (en) | 2014-09-24 | 2015-09-20 | Compositions and methods for selective GI tract delivery |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462054456P | 2014-09-24 | 2014-09-24 | |
US62/054,456 | 2014-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016046817A1 true WO2016046817A1 (en) | 2016-03-31 |
Family
ID=55580410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2015/050951 WO2016046817A1 (en) | 2014-09-24 | 2015-09-20 | Compositions and methods for selective gi tract delivery |
Country Status (4)
Country | Link |
---|---|
US (1) | US11229600B2 (en) |
EP (1) | EP3197436B1 (en) |
ES (1) | ES2919874T3 (en) |
WO (1) | WO2016046817A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3278793A1 (en) * | 2016-08-04 | 2018-02-07 | ppsph. GmbH | Composition for the treatment of veisalgia |
CN109562070A (en) * | 2016-03-30 | 2019-04-02 | 生命饮料全球公司 | Composition and method for the delivering of selective gastrointestinal tract |
WO2019182461A1 (en) * | 2018-03-19 | 2019-09-26 | Universidad César Vallejo S.A.C. | Anti fungal sachet formulations, use thereof on fruit in the post-harvest stage and method for preparing said formulations |
US11439162B2 (en) * | 2018-10-11 | 2022-09-13 | Vitiprints, LLC | Dissolvable composition having indicia |
US11510877B2 (en) | 2017-10-10 | 2022-11-29 | Capsugel Belgium Nv | Gelling multiparticulates |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3855943A2 (en) * | 2018-09-27 | 2021-08-04 | Société des Produits Nestlé S.A. | Compositions and methods using at least one glycine or derivative thereof, at least one n-acetylcysteine or derivative thereof, and at least one nicotinamide riboside or nad+ precursor |
US20210353655A1 (en) * | 2020-05-15 | 2021-11-18 | Brilliant Lab LLC | Plant-based phytonutrient composition for regulation of signal transduction cascades in the body and related methods |
GR1010117B (en) | 2020-07-14 | 2021-11-08 | Uni Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, | Nutritional suppplement for the oral administration of a combination of dihydromyrisetin, choline and one or more vitamins exhibiting antioxydant action useful for the normal function of the liver |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6011562A (en) | 1997-08-01 | 2000-01-04 | Avid Technology Inc. | Method and system employing an NLE to create and modify 3D animations by mixing and compositing animation data |
US6022562A (en) * | 1994-10-18 | 2000-02-08 | Flamel Technologies | Medicinal and/or nutritional microcapsules for oral administration |
WO2006039022A2 (en) | 2004-08-27 | 2006-04-13 | Spherics, Inc. | Controlled regional oral delivery |
US20070202215A1 (en) | 2006-02-28 | 2007-08-30 | Zahramehran Salari Lak | Dietary nutritional supplements for persons consuming alcohol products |
US8163307B2 (en) | 2005-01-07 | 2012-04-24 | Biolex Therapeutics, Inc. | Controlled release compositions for interferon based PEGT/PBT block copolymers and method for preparation thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5160742A (en) * | 1991-12-31 | 1992-11-03 | Abbott Laboratories | System for delivering an active substance for sustained release |
JPH10510540A (en) * | 1994-12-12 | 1998-10-13 | オメロス メディカル システムズ,インコーポレーテッド | Irrigation solutions and methods for controlling pain, inflammation and convulsions |
PL338217A1 (en) * | 1997-07-19 | 2000-10-09 | Keeco Uk Ltd | Method of and apparatus for mixing liquid and powdered substances with each other and for conducting a reaction between them |
KR100387245B1 (en) * | 1997-10-17 | 2003-08-19 | 일양약품주식회사 | Enteric coated microgranules for stabilizing lactic acid bacteria |
US6340478B1 (en) * | 1999-06-07 | 2002-01-22 | Bio Dar Ltd. | Microencapsulated and controlled-release herbal formulations |
IT1318625B1 (en) | 2000-07-14 | 2003-08-27 | Roberto Valducci | ORAL SOLID PHARMACEUTICAL FORMULATIONS WITH MULTI-PHASE RELEASE - EMPLOYEE. |
US20020106408A1 (en) * | 2000-12-01 | 2002-08-08 | Johnatan Bacon | Prolamin-based sustained-release compositions and delayed-onset compositions |
CA2447693A1 (en) * | 2001-05-31 | 2002-12-05 | Cima Labs Inc. | Taste-masking of highly water-soluble drugs |
DE10250543A1 (en) * | 2002-10-29 | 2004-05-19 | Röhm GmbH & Co. KG | Multilayer dosage form |
US7943166B2 (en) * | 2003-04-10 | 2011-05-17 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
CA2581775A1 (en) * | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Dihydropyrimidine microcapsule - formulations |
EP2104434A1 (en) * | 2006-09-19 | 2009-09-30 | Technion Research and Development Foundation Ltd. | Probiotic compositions and methods of making same |
US8119156B2 (en) * | 2006-10-24 | 2012-02-21 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
EP2190418B1 (en) * | 2007-08-15 | 2013-10-02 | Mcneil-PPC, Inc | Immediate release and sustained release ibuprofen dosing regimen |
EP2229364B1 (en) * | 2007-12-05 | 2015-02-25 | Janssen Pharmaceutica, N.V. | Dibenzoazepine and dibenzooxazepine trpa1 agonists |
WO2009079537A1 (en) | 2007-12-17 | 2009-06-25 | New World Pharmaceuticals, Llc | Sustained release of nutrients in vivo |
WO2009086940A1 (en) * | 2008-01-10 | 2009-07-16 | Evonik Röhm Gmbh | Coated pharmaceutical or nutraceutical preparation with enhanced active substance release in the colon |
SI2341899T1 (en) * | 2008-09-24 | 2015-04-30 | Evonik Roehm Gmbh | Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol |
EP2326313B1 (en) * | 2008-09-24 | 2015-03-04 | Evonik Röhm GmbH | Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol |
US20100104675A1 (en) * | 2008-10-28 | 2010-04-29 | Pablo Kizelsztein | Method Of Treating Demyelinating Central Nervous System Diseases |
CN102215857B (en) * | 2008-11-19 | 2015-06-17 | 庆熙大学校产学协力团 | Pharmaceutical composition containing ginger extract or shogaol |
US20100196554A1 (en) | 2009-02-03 | 2010-08-05 | Tropicana Products, Inc. | Microencapsulated citrus phytochemicals comprising citrus limonoids and application to beverages |
WO2011103920A2 (en) * | 2010-02-25 | 2011-09-01 | Evonik Röhm Gmbh | Pharmaceutical or neutraceutical formulation |
HU230560B1 (en) | 2010-07-30 | 2016-12-28 | Péter Hajnal | Ph dependent pulsatile and sustained release pharmaceutical composition |
EP2651242A1 (en) * | 2010-12-13 | 2013-10-23 | Intercontinental Great Brands LLC | Delivery of functional compounds |
JP2014506894A (en) * | 2011-02-28 | 2014-03-20 | テクノロジーズ・クロロス・インク | Chewable vehicle for oral absorption |
US20120263828A1 (en) * | 2011-04-17 | 2012-10-18 | Ackley Donald E | Stabilization of Oil in Water Microparticles Using Natural Polymeric Polyphenols |
US20130034632A1 (en) * | 2011-08-02 | 2013-02-07 | John Cuomo | Nutritional supplements containing lipoic acids and sulfur containing compounds |
CA2877502C (en) * | 2012-08-27 | 2019-07-30 | Evonik Industries Ag | Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol |
RU2015110824A (en) * | 2012-08-27 | 2016-10-20 | Эвоник Индустрис Аг | PHARMACEUTICAL OR NUTRICEVITIC COMPOSITION WITH SLOW DELIVERY AND RESISTANCE TO ETHANOL |
CA2926082C (en) * | 2013-10-07 | 2022-06-14 | Impax Laboratories, Inc. | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
-
2015
- 2015-09-20 WO PCT/IL2015/050951 patent/WO2016046817A1/en active Application Filing
- 2015-09-20 EP EP15845037.9A patent/EP3197436B1/en active Active
- 2015-09-20 ES ES15845037T patent/ES2919874T3/en active Active
- 2015-09-20 US US15/513,672 patent/US11229600B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022562A (en) * | 1994-10-18 | 2000-02-08 | Flamel Technologies | Medicinal and/or nutritional microcapsules for oral administration |
US6011562A (en) | 1997-08-01 | 2000-01-04 | Avid Technology Inc. | Method and system employing an NLE to create and modify 3D animations by mixing and compositing animation data |
WO2006039022A2 (en) | 2004-08-27 | 2006-04-13 | Spherics, Inc. | Controlled regional oral delivery |
US8163307B2 (en) | 2005-01-07 | 2012-04-24 | Biolex Therapeutics, Inc. | Controlled release compositions for interferon based PEGT/PBT block copolymers and method for preparation thereof |
US20070202215A1 (en) | 2006-02-28 | 2007-08-30 | Zahramehran Salari Lak | Dietary nutritional supplements for persons consuming alcohol products |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109562070A (en) * | 2016-03-30 | 2019-04-02 | 生命饮料全球公司 | Composition and method for the delivering of selective gastrointestinal tract |
EP3435983A4 (en) * | 2016-03-30 | 2019-12-18 | Vital Beverages Global Inc. | Compositions and methods for selective gi tract delivery |
EP3278793A1 (en) * | 2016-08-04 | 2018-02-07 | ppsph. GmbH | Composition for the treatment of veisalgia |
WO2018024887A1 (en) * | 2016-08-04 | 2018-02-08 | Ppsph. Gmbh | Composition for the treatment of veisalgia |
CN109715168A (en) * | 2016-08-04 | 2019-05-03 | Ph股份公司 | For treating the composition being still drank after a night |
US20190350888A1 (en) * | 2016-08-04 | 2019-11-21 | Ph. Ag | Composition for the treatment of veisalgia |
RU2757379C2 (en) * | 2016-08-04 | 2021-10-14 | Пх. Аг | Composition for the treatment of veisalgia |
US11510877B2 (en) | 2017-10-10 | 2022-11-29 | Capsugel Belgium Nv | Gelling multiparticulates |
WO2019182461A1 (en) * | 2018-03-19 | 2019-09-26 | Universidad César Vallejo S.A.C. | Anti fungal sachet formulations, use thereof on fruit in the post-harvest stage and method for preparing said formulations |
US11439162B2 (en) * | 2018-10-11 | 2022-09-13 | Vitiprints, LLC | Dissolvable composition having indicia |
Also Published As
Publication number | Publication date |
---|---|
EP3197436A1 (en) | 2017-08-02 |
US11229600B2 (en) | 2022-01-25 |
ES2919874T3 (en) | 2022-07-28 |
US20170290768A1 (en) | 2017-10-12 |
EP3197436B1 (en) | 2022-03-09 |
EP3197436A4 (en) | 2018-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3197436B1 (en) | Compositions and methods for selective gi tract delivery | |
Borghi et al. | Nutraceuticals with a clinically detectable blood pressure‐lowering effect: a review of available randomized clinical trials and their meta‐analyses | |
US7445807B2 (en) | Agglomerated granular protein-rich nutritional supplement | |
US7300665B2 (en) | Nocturnal muscle enhancing composition and method | |
Li et al. | Microencapsulation of vitamins, minerals, and nutraceuticals for food applications | |
KR20190026648A (en) | Compositions and methods for selective gastrointestinal tract delivery | |
US20170348235A1 (en) | Multi-phase release of sports nutrition and energy drink compositions utilizing lipid particulates | |
RU2433752C2 (en) | Tasteless nutritive supplement containing free amino acids | |
JPH11500725A (en) | Use of piperine as a bioavailability enhancer | |
US20070243211A1 (en) | Compositions for regulating metabolic disorders and methods of use thereof | |
JP2006077024A (en) | Co-beadlet of dha and rosemary, and using method thereof | |
US20060182729A1 (en) | Combat/training antioxidant micronutrient formulation and method of administration | |
US20200338153A1 (en) | Anaerobic antioxidant composition | |
CA3041914C (en) | Anaerobic antioxidant composition | |
RU2436415C2 (en) | Composition of biologically active substances based on betulin with regulated rate of releasing components for reducing degree of alcohol intoxication, preventing and relieving alcohol intoxication and alcohol withdrawal syndrome | |
US20050008699A1 (en) | Effervescent glucosamine composition | |
EP3733197A1 (en) | Anaerobic antioxidant composition | |
JP7170770B2 (en) | oral composition | |
JP7170771B2 (en) | oral composition | |
AU2021201861A1 (en) | Anaerobic antioxidant composition | |
JP7123404B2 (en) | Functional oral composition and manufacturing method thereof | |
JP5434907B2 (en) | Nutritional improvement composition | |
US20170071859A1 (en) | Multi-phase release of sports nutrition and energy drink compositions utilizing lipid particulates | |
PL235837B1 (en) | High-dose dietary supplements containing active substances having a physiological effect in the form of effervescent tablets, with high stability, for preparation of solutions or suspensions, and processes for their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15845037 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15513672 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015845037 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015845037 Country of ref document: EP |